image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
2ec57c5ecd732368d90ca605190925d8a0e64445abf6eaefcb7b46c662c7280b.png | complex | <table><tr><td>Clinicopathological features</td><td>n</td><td colspan="2"><i>BICD1</i> expression, n (%)</td><td rowspan="2"><i>P</i></td></tr><tr><td></td><td>523</td><td>Low, n=262 (50.1)</td><td>High, n=261 (49.9)</td></tr><tr><td>Age</td><td></td><td></td><td></td><td>0.089722</td></tr><tr><td> <65</td><td>347</td><td>183 (52.7)</td><td>164 (47.3)</td><td></td></tr><tr><td> ≥65</td><td>176</td><td>79 (44.9)</td><td>97 (55.1)</td><td></td></tr><tr><td>Gender</td><td></td><td></td><td></td><td>0.136863</td></tr><tr><td> Female</td><td>205</td><td>111 (54.1)</td><td>94 (45.9)</td><td></td></tr><tr><td> Male</td><td>318</td><td>151 (47.5)</td><td>167 (52.5)</td><td></td></tr><tr><td><i>MGMT</i> expression</td><td></td><td></td><td></td><td>0.204737</td></tr><tr><td> Low</td><td>262</td><td>124 (47.3)</td><td>138 (52.7)</td><td></td></tr><tr><td> High</td><td>261</td><td>138 (52.9)</td><td>123 (47.1)</td><td></td></tr><tr><td>Overall survival indicator</td><td></td><td></td><td></td><td>0.712211</td></tr><tr><td> 0 (censor)</td><td>89</td><td>43 (48.3)</td><td>46 (51.7)</td><td></td></tr><tr><td> 1 (death)</td><td>434</td><td>219 (50.5)</td><td>215 (49.5)</td><td></td></tr><tr><td>Molecular Subclassification</td><td></td><td></td><td></td><td></td></tr><tr><td> Neural</td><td>87</td><td>70 (80.5)</td><td>17 (19.5)</td><td><0.00001</td></tr><tr><td> Proneural</td><td>138</td><td>91 (65.9)</td><td>47 (34.1)</td><td></td></tr><tr><td> Mesenchymal</td><td>156</td><td>71 (45.5)</td><td>85 (54.5)</td><td></td></tr><tr><td> Classical</td><td>142</td><td>30 (21.1)</td><td>112 (78.9)</td><td></td></tr></table> |
72853a20eb42c67209a174e6710c97e145b90e8ef9cca213988a6cae32e52b53.png | simple | <table><tr><td>Variable</td><td>Opium addicted N=50</td><td>Non addicted N=50</td><td>P value</td></tr><tr><td>Age Mean±SD</td><td>36.00±6.54</td><td>35.38±6.7</td><td>0.64</td></tr><tr><td>BMI Mean±sD</td><td>21.96±3.46</td><td>24.27±3.85</td><td>0.002</td></tr><tr><td>Cigarrette smoking No. (%)</td><td>37 (77.1)</td><td>34 (61)</td><td>0.31</td></tr><tr><td>Vertebral BMD frequency (%)</td><td></td><td></td><td></td></tr><tr><td>Normal</td><td>22 (44)</td><td>37 (74)</td><td>0.002</td></tr><tr><td>Osteopenia</td><td>28 (56)</td><td>13 (26)</td><td></td></tr><tr><td>Lumbar measurement Mean±SD</td><td>0.92±0.12</td><td>1.01±0.12</td><td>0.001</td></tr></table> |
0db75bfcda2ad762c7e7738ed1efb5556b83d87bd046d6ba50dcd97a63959912.png | simple | <table><tr><td>National policies and guidelines</td></tr><tr><td>Recording and Reporting tools</td></tr><tr><td>Collaboration and communication between TB and HIV control programmes</td></tr><tr><td>Leadership and commitment</td></tr><tr><td>Target setting at all levels of the health care system</td></tr><tr><td>Human resources: recruitment, training, support, task shifting</td></tr><tr><td>Financing</td></tr><tr><td>National Partnerships for results</td></tr><tr><td>Providing TB and HIV services under one roof</td></tr></table> |
c0c68027b707338e960213efd58f9a102a3953aaa0e616976b5298e668cf1cbe.png | complex | <table><tr><td>Gene</td><td>Primers</td></tr><tr><td rowspan="2">ABCG2</td><td>Primer1: 5′-TGGCTTAGACTCAAGCACAGC-3′</td></tr><tr><td>Primer2: 5′- TGGTCCCTGCTTAGACATCC-3′</td></tr><tr><td rowspan="2">MRP1</td><td>Primer1: 5′-TGTGGGAAAACACATCTTTGA-3′</td></tr><tr><td>Primer2: 5′-CTGTGCGTGACCAAGATCC-3′</td></tr><tr><td rowspan="2">MRP2</td><td>Primer1: 5′-AGTGAATGACATCTTCACGTTTG-3′</td></tr><tr><td>Primer2: 5′-CTTGCAAAGGAGATCAGCAA-3′</td></tr><tr><td rowspan="2">MDR1</td><td>Primer1: 5′-ACAGAAAGCGAAGCAGTGGT-3′</td></tr><tr><td>Primer2: 5′-ATGGTGGTCCGACCT TTTC-3′</td></tr><tr><td rowspan="2">CD44</td><td>Primer1: 5′-GCCTTGGCTTTGATTCTTGC-3′</td></tr><tr><td>Primer2: 5′-TCCACTTGGCTTTCTGTCCTC-3′</td></tr><tr><td rowspan="2">HES1</td><td>Primer1: 5′-GAAAGATAGCTCGCGGCAT-3′</td></tr><tr><td>Primer2: 5′'-GAAGCGGGTCACCTCGTT-3′</td></tr><tr><td rowspan="2">Krt15</td><td>Primer1: 5′-GCTGCTTGACATAAAGACACG-3′</td></tr><tr><td>Primer2: 5′'-ATTGCTGCTGCTACCACCA-3′</td></tr><tr><td rowspan="2">Oct-4</td><td>Primer1: 5′-GGAAGGTATTCAGCCAAACGACCA-3′</td></tr><tr><td>Primer2: 5′'-CTCACTCGGTTCTCGATACTGGTT-3′</td></tr><tr><td rowspan="2">Sox2</td><td>Primer1: 5′-TTCGATCCCAACTTTCCAT-3′</td></tr><tr><td>Primer2: 5′'-ACATGGATTCTCGGCAGAC-3′</td></tr><tr><td rowspan="2">GAPDH</td><td>Primer1: 5′-GCCGGTGCTGAATATGTC-3′</td></tr><tr><td>Primer2: 5′-CTTCTGGGTGGCAGTGAT-3′</td></tr></table> |
ac207fbd473ca55c8e20c3b1464bea4ec14c9df5824171be817c47ddbaff909c.png | simple | <table><tr><td>Age</td><td>Number of Pupils (%)</td></tr><tr><td>16–17</td><td>214 (24.2)</td></tr><tr><td>18–19</td><td>397 (44.9)</td></tr><tr><td>20–22</td><td>272 (30.8)</td></tr><tr><td>Total</td><td>883</td></tr></table> |
623dbfe63a11383f16e216280260433c77fd614b691577e3d678cfcb58857de1.png | simple | <table><tr><td>Study</td><td>Running distance</td><td>Running period</td><td>OA induced</td><td>Method</td><td>Effect</td></tr><tr><td>Sekiya et al. [5] 2009</td><td>30 km</td><td>6 weeks</td><td>No</td><td></td><td>Harmful</td></tr><tr><td>Siebelt et al. [24] 2011</td><td>31.8 km</td><td>6 weeks</td><td>No</td><td></td><td>Harmful</td></tr><tr><td>Beckett et al. [17] 2012</td><td>30 km / 55 km</td><td>3 / 6 weeks</td><td>No</td><td></td><td>Harmful</td></tr><tr><td>Pap et al. [20] 1998</td><td>30 km</td><td>12 weeks</td><td>Yes</td><td>Intracranial self stimulation</td><td>Harmful</td></tr><tr><td>Siebelt et al. [21] 2014</td><td>15 km</td><td>6 weeks</td><td>Yes</td><td>Papain injection</td><td>Harmful</td></tr><tr><td>Saito et al. 2015</td><td>15 km</td><td>3 weeks</td><td>Yes</td><td>MIA 0.1 mg injection</td><td>Harmful</td></tr><tr><td>Galois et al. [22] 2004</td><td>15 km</td><td>4 weeks</td><td>Yes</td><td>ACLT</td><td>Beneficial</td></tr><tr><td>Cifuentes et al. [23] 2010</td><td>15 km</td><td>8 weeks</td><td>Yes</td><td>MIA 1.2 mg injection</td><td>Beneficial</td></tr></table> |
f7badf89095a359bc54cd70cdeb628f2ee173a0aa3a8bfda8d6ac4c09f6aed89.png | simple | <table><tr><td></td><td>Baseline Value</td><td>Source(s)</td></tr><tr><td>Input variables</td><td></td><td></td></tr><tr><td> Chest pain is caused by ACS</td><td>0.1</td><td>[19-22]</td></tr><tr><td> GP Sensitivity with ECG</td><td>0.818</td><td>Unpublished data from [8,11-16]</td></tr><tr><td> GP Sensitivity without ECG</td><td>0.667</td><td>Unpublished data from [8]</td></tr><tr><td> GP Specificity with ECG</td><td>0.5</td><td>[12-16]</td></tr><tr><td> GP Specificity without ECG</td><td>0.3</td><td>[17]</td></tr><tr><td> Correctly referred STEMI patients receiving thrombolysis (%)</td><td>58.5</td><td>[6]</td></tr><tr><td> Relative risk reduction of thrombolytics</td><td>0.750</td><td>[23,24]</td></tr><tr><td>Costs (2007 US$)</td><td></td><td></td></tr><tr><td> GP visit</td><td>1.76</td><td>[37]</td></tr><tr><td> ECG</td><td>1.93</td><td>[39,40,42-44]</td></tr><tr><td> Emergency department visit</td><td>3.48</td><td>[37]</td></tr><tr><td> Streptokinase</td><td>117.00</td><td>[38,45]</td></tr><tr><td> Admission</td><td>157.55</td><td>[37]</td></tr><tr><td> Blood transfusion</td><td>107.67</td><td>[37]</td></tr><tr><td> Stroke</td><td>211.37</td><td>[37]</td></tr><tr><td> Annual secondary prevention</td><td>16.56</td><td>[37,38]</td></tr></table> |
0a3192fb9c38c35fd588c4ba7efa23b3a168f37454df7653e9425d69677847c1.png | simple | <table><tr><td>#</td><td>Author</td><td>Year</td><td>Compound</td><td>Strain</td><td>Dose</td><td>Rote</td><td>Test</td><td>(Model)</td></tr><tr><td>1</td><td>Nagase <i>et al</i>. </td><td>2002 </td><td>TAN-67 </td><td>SD </td><td>1-10 mg/kg </td><td>s.c. </td><td>FSS </td><td></td></tr><tr><td>2</td><td>Broom <i>et al</i>. </td><td>2002 </td><td>SNC80 </td><td>SD </td><td>10-100 mg/kg </td><td>s.c. </td><td>FSS </td><td></td></tr><tr><td>3</td><td>Broom <i>et al</i>. </td><td>2002 </td><td>(+) BW373U86 </td><td>SD </td><td>1-10 mg/kg </td><td>s.c. </td><td>FSS </td><td></td></tr><tr><td>4</td><td>Saitoh <i>et al</i>. </td><td>2004 </td><td>SNC80 </td><td>ICR </td><td>0.3-3 mg/kg </td><td>s.c. </td><td>FSS/CSM </td><td></td></tr><tr><td>5</td><td>Torregrossa <i>et al</i>. </td><td>2005 </td><td>(+) BW373U86 </td><td>SD </td><td>10 mg/kg X 1, 8, 21 days </td><td>s.c. </td><td>FSS </td><td></td></tr><tr><td>6</td><td>Naidu <i>et al</i>. </td><td>2007 </td><td>(-) NIH11082 </td><td>C57BL6 </td><td>8-32 mg/kg </td><td>i.p. </td><td>TST </td><td></td></tr><tr><td>7</td><td>Saitoh <i>et al</i>. </td><td>2008 </td><td>SNC80 </td><td>Wistar </td><td>1-10 mg/kg X 7 days </td><td>s.c. </td><td>HE </td><td>OB rat model</td></tr><tr><td>8</td><td>Vergra <i>et al</i>. </td><td>2008 </td><td>UFP-512 </td><td>Swiss </td><td>0.001-0.1 nmol/0.01-1 mg/kg </td><td>i.c.v./i.p. </td><td>FSS </td><td></td></tr><tr><td>9</td><td></td><td></td><td>UFP-512 </td><td>SD </td><td>0.1-1 mg/kg </td><td>i.p. </td><td>FSS </td><td></td></tr><tr><td>10</td><td>Le Bourdonnec <i>et al</i>. </td><td>2008 </td><td>ADL5859 </td><td>- </td><td>0.3-3 mg/kg </td><td>p.o. </td><td>FSS </td><td></td></tr><tr><td>11</td><td>Saitoh <i>et al</i>. </td><td>2011 </td><td>KNT-127 </td><td>ICR </td><td>0.1-1 mg/kg </td><td>s.c. </td><td>FSS </td><td></td></tr><tr><td>12</td><td>Hudzik <i>et al</i>. </td><td>2011 </td><td>AZD2327 </td><td>SD </td><td>1-10 mg/kg X 4 days </td><td>p.o. </td><td>LH </td><td></td></tr></table> |
dccc0ff396df7b6b7993a2c3254dd81306b8442c3dd00f48f118d0cbd3bd63d6.png | complex | <table><tr><td> </td><td colspan="5">Predictability of Spherical Equivalent*</td><td> </td></tr><tr><td> </td><td>undercorrection <1.0</td><td>1.0 to 0.51</td><td>±0.5</td><td>0.51 to 1.0</td><td>overcorrection >1.0</td><td>Total</td></tr><tr><td> </td><td colspan="5">WTR</td><td> </td></tr><tr><td>Number</td><td>1</td><td>9</td><td>34</td><td>6</td><td>0</td><td>50</td></tr><tr><td><i>%</i></td><td><i>2</i></td><td><i>18</i></td><td><i>68</i></td><td><i>12</i></td><td><i>0</i></td><td><i>100</i></td></tr><tr><td> </td><td colspan="5">Oblique</td><td> </td></tr><tr><td>Number</td><td>3</td><td>8</td><td>38</td><td>9</td><td>0</td><td>58</td></tr><tr><td><i>%</i></td><td><i>5</i></td><td><i>14</i></td><td><i>66</i></td><td><i>16</i></td><td><i>0</i></td><td><i>100</i></td></tr><tr><td> </td><td colspan="5">ATR</td><td> </td></tr><tr><td>Number</td><td>1</td><td>6</td><td>30</td><td>7</td><td>1</td><td>45</td></tr><tr><td><i>%</i></td><td><i>2</i></td><td><i>13</i></td><td><i>67</i></td><td><i>16</i></td><td><i>2</i></td><td><i>100</i></td></tr></table> |
1044620b1ad4c08b5638a7646d91c908871f8ed1ba85b9aa229b2d9927a297dd.png | complex | <table><tr><td rowspan="2">Y-Intercept (#/cm<sup>3</sup>)</td><td colspan="2">Weekday</td><td colspan="2">Weekend</td></tr><tr><td>Day</td><td>Night</td><td>Day</td><td>Night</td></tr><tr><td>Ultrafine </td><td>50 (5)</td><td>101 (8)</td><td>43 (11)</td><td>143 (7)</td></tr><tr><td>Fine </td><td>48 (2)</td><td>62 (2)</td><td>46 (5)</td><td>90 (3)</td></tr></table> |
2bb1698bae0b79c0cb1d22063d21bdcbf361bb08f33ea176af1bb4c2400a4f21.png | complex | <table><tr><td>QUICKI</td><td></td><td colspan="2">tertile 1</td><td colspan="2">tertile 2</td><td colspan="2">tertile 3</td></tr><tr><td></td><td>Model</td><td># events</td><td>HR (95%CI)</td><td># events</td><td>HR (95%CI)</td><td># events</td><td>HR (95%CI)</td></tr><tr><td>All vascular events</td><td>1</td><td>48</td><td>1.70 (1.05-2.74)</td><td>52</td><td>1.86 (1.16-2.98)</td><td>26</td><td>1 (reference)</td></tr><tr><td></td><td>2</td><td></td><td>1.78 (1.10-2.89)</td><td></td><td>1.92 (1.20-3.08)</td><td></td><td>1 (reference)</td></tr><tr><td></td><td>3</td><td></td><td>1.79 (1.10-2.90)</td><td></td><td>1.86 (1.16-3.00)</td><td></td><td>1 (reference)</td></tr><tr><td></td><td>4</td><td></td><td>1.50 (0.85-2.68)</td><td></td><td>1.80 (1.10-2.96)</td><td></td><td>1 (reference)</td></tr><tr><td>Myocardial infarction</td><td>1</td><td>27</td><td>1.42 (0.77-2.61)</td><td>30</td><td>1.63 (0.90-2.96)</td><td>17</td><td>1 (reference)</td></tr><tr><td></td><td>2</td><td></td><td>1.41 (0.76-2.61)</td><td></td><td>1.61 (0.89-2.93)</td><td></td><td>1 (reference)</td></tr><tr><td></td><td>3</td><td></td><td>1.39 (0.75-2.59)</td><td></td><td>1.57 (0.86-2.85)</td><td></td><td>1 (reference)</td></tr><tr><td></td><td>4</td><td></td><td>0.95 (0.46-1.98)</td><td></td><td>1.34 (0.72-2.51)</td><td></td><td>1 (reference)</td></tr><tr><td>All cause mortality</td><td>1</td><td>32</td><td>1.43 (0.82-2.51)</td><td>39</td><td>1.69 (0.99-2.91)</td><td>20</td><td>1 (reference)</td></tr><tr><td></td><td>2</td><td></td><td>1.56 (0.88-2.75)</td><td></td><td>1.80 (1.05-3.10)</td><td></td><td>1 (reference)</td></tr><tr><td></td><td>3</td><td></td><td>1.63 (0.92-2.88)</td><td></td><td>1.76 (1.02-3.03)</td><td></td><td>1 (reference)</td></tr><tr><td></td><td>4</td><td></td><td>1.56 (0.78-3.09)</td><td></td><td>1.83 (1.04-3.24)</td><td></td><td>1 (reference)</td></tr><tr><td>Vascular mortality</td><td>1</td><td>15</td><td>1.50 (0.66-3.43)</td><td>23</td><td>2.26 (1.04-4.88)</td><td>9</td><td>1 (reference)</td></tr><tr><td></td><td>2</td><td></td><td>1.72 (0.74-3.98)</td><td></td><td>2.42 (1.12-5.25)</td><td></td><td>1 (reference)</td></tr><tr><td></td><td>3</td><td></td><td>1.74 (0.75-4.04)</td><td></td><td>2.24 (1.03-4.88)</td><td></td><td>1 (reference)</td></tr><tr><td></td><td>4</td><td></td><td>1.85 (0.73-4.73)</td><td></td><td>2.56 (1.15-5.70)</td><td></td><td>1 (reference)</td></tr></table> |
0ecf6f7e1bda0771caa2c96807664bbba53e20cd46c6776ac41fd34f23fd9696.png | complex | <table><tr><td></td><td colspan="2">TBIC practice</td><td></td><td></td></tr><tr><td>Variables</td><td>Proper</td><td>Improper</td><td>COR 95 % CI</td><td>AOR 95 % CI</td></tr><tr><td colspan="5">Site of health facility</td></tr><tr><td> Urban</td><td>82</td><td>139</td><td>0.94 (0.67,1.32)</td><td></td></tr><tr><td> Rural</td><td>158</td><td>252</td><td>1</td><td></td></tr><tr><td colspan="5">Sex</td></tr><tr><td> Male</td><td>148</td><td>237</td><td>1.05 (0.75,1.45)</td><td></td></tr><tr><td> Female</td><td>92</td><td>154</td><td>1</td><td></td></tr><tr><td colspan="5">Educational level</td></tr><tr><td> Degree</td><td>79</td><td>78</td><td>1.97 (1.37,2.84)</td><td>1.20 (0.77,1.89)</td></tr><tr><td> Diploma</td><td>161</td><td>313</td><td>1</td><td></td></tr><tr><td colspan="5">Age category</td></tr><tr><td> 25–34 years</td><td>132</td><td>210</td><td>1.21 (0.86,1.70)</td><td>0.84 (0.56,1.26)</td></tr><tr><td>> 34 years</td><td>22</td><td>15</td><td>2.83 (1.40,5.74)</td><td>1.20(0.54,2.67)</td></tr><tr><td> 18–24 years</td><td>86</td><td>166</td><td>1</td><td>1</td></tr><tr><td colspan="5">Experience category</td></tr><tr><td> 3–5 years</td><td>65</td><td>80</td><td>1.76 (1.19,2.61)</td><td>1.11 (0.68,1.79)</td></tr><tr><td> 5–10 years</td><td>29</td><td>26</td><td>2.42 (1.37,4.29)</td><td>1.73 (0.85,3.52)</td></tr><tr><td>> 10 years</td><td>23</td><td>18</td><td>2.77 (1.44,5.33)</td><td>1.05 (0.35,3.13)</td></tr><tr><td> 1–3 years</td><td>123</td><td>267</td><td></td><td>1</td></tr><tr><td colspan="5">Profession</td></tr><tr><td> Health officer</td><td>44</td><td>37</td><td>6.34(2.98,13.51)</td><td>3.00(0.20,45.6)</td></tr><tr><td> Laboratory technologist</td><td>24</td><td>46</td><td>2.78(1.26,6.13)</td><td>1.56(0.13,19.36)</td></tr><tr><td> Midwifery</td><td>13</td><td>56</td><td>1.24(0.52,2.93)</td><td>2.29(0.15,35.58)</td></tr><tr><td> Nurse</td><td>147</td><td>188</td><td>4.17(2.17,8.01)</td><td>3.48(0.25,49.35)</td></tr><tr><td> pharmacy</td><td>12</td><td>64</td><td>1</td><td>1</td></tr><tr><td colspan="5">Working department</td></tr><tr><td> TB clinic</td><td>42</td><td>10</td><td>22.40(8.88,56.49)</td><td>10.17(3.81,27.17)*</td></tr><tr><td> Adult OPD</td><td>82</td><td>105</td><td>4.17(2.11,8.23)</td><td>3.23(1.54,6.79)*</td></tr><tr><td> Under 5 OPD</td><td>27</td><td>48</td><td>3.00(1.38,6.52)</td><td>2.02(0.87,4.69)</td></tr><tr><td> Laboratory</td><td>24</td><td>46</td><td>2.78(1.26,6.13)</td><td>1.71(0.73,4.00)</td></tr><tr><td> ART Clinic and IPD</td><td>24</td><td>34</td><td>3.77(1.68,8.45)</td><td>2.74(1.13,6.63)*</td></tr><tr><td> MCH room</td><td>29</td><td>84</td><td>1.84(0.87,3.89)</td><td>1.63(0.72,3.67)</td></tr><tr><td> Pharmacy</td><td>12</td><td>64</td><td>1</td><td>1</td></tr><tr><td colspan="5">Training on TBIC</td></tr><tr><td> Yes</td><td>122</td><td>96</td><td>3.18 (2.26,4.47)</td><td>1.30 (0.83,2.04)</td></tr><tr><td> No</td><td>118</td><td>295</td><td>1</td><td>1</td></tr><tr><td colspan="5">Knowledge presence of TBIC plan</td></tr><tr><td> Yes</td><td>221</td><td>239</td><td>7.40 (4.44,12.32)</td><td>4.25 (2.46,7.35)*</td></tr><tr><td> No</td><td>19</td><td>152</td><td>1</td><td>1</td></tr><tr><td colspan="5">Know presence of national guideline for TBIC</td></tr><tr><td> Yes</td><td>231</td><td>247</td><td>14.96 (7.45,30.04)</td><td>8.95 (4.35,18.40)*</td></tr><tr><td> No</td><td>9</td><td>144</td><td>1</td><td>1</td></tr></table> |
4e8d5398eb3511e739d10625578b01be74ce4929e02a19ef0f20554c510eb9b2.png | simple | <table><tr><td></td><td>Haddadi <i>et al.</i></td><td>Huang <i>et al.</i></td><td>Lu &Zoubir</td><td>Ours</td></tr><tr><td><i>E</i>(<i>l<sub>q</sub></i>)</td><td>Lawley</td><td>Lawley</td><td>Lawley</td><td>Lawley</td></tr><tr><td><i>Var</i>(<i>l<sub>q</sub></i>)</td><td>Multivariate Statistics</td><td>Random Matrix</td><td>Random Matrix</td><td>Lawley</td></tr><tr><td><i>E</i>(<i>A<sub>q</sub></i>)</td><td>Lawley</td><td>Lawley</td><td>Lawley</td><td>Lawley</td></tr><tr><td><i>Var</i>(<i>A<sub>q</sub></i>)</td><td>- *</td><td>-</td><td>Random Matrix</td><td>Random Matrix</td></tr></table> |
acb61adaffa4adf606c1a173e586e8f98fedba6b638f965a14bd915e11d5d836.png | simple | <table><tr><td>Disability</td><td>No or Other Resistance (n = 220)</td><td>INH Resistant (n = 86)</td><td>RIF Resistant or MDR (n = 16)</td><td>Cumulative Odds Ratio<sup>a</sup>(95% CI)</td><td><i>P</i> Value</td></tr><tr><td>Good</td><td>91 (41.4)</td><td>31 (36.0)</td><td>2 (12.5)</td><td>INH: 1.44</td><td></td></tr><tr><td>Intermediate</td><td>53 (24.1)</td><td>17 (19.8)</td><td>0 (0)</td><td>(.90–2.32)</td><td>.13</td></tr><tr><td>Severe</td><td>20 (9.1)</td><td>11 (12.8)</td><td>3 (18.8)</td><td>RIF MDR: 10.31</td><td></td></tr><tr><td>Death</td><td>52 (23.6)</td><td>27 (31.4)</td><td>11 (68.8)</td><td>(3.39–31.36)</td><td><.001</td></tr></table> |
c0147b4dacb9d84a4c0111a0ab594a377157c92d39103eef3d3587bf40f9e577.png | complex | <table><tr><td></td><td>N</td><td>M ± SD</td></tr><tr><td colspan="3">Outcome: Teaching quality<sup>a</sup></td></tr><tr><td> Didactics</td><td>499</td><td>7.9 ± 1.3</td></tr><tr><td> Learning climate</td><td>500</td><td>8.4 ± 1.1</td></tr><tr><td> Motivation and enthusiasm</td><td>500</td><td>8.1 ± 1.3</td></tr><tr><td> Behavior towards patients</td><td>488</td><td>8.1 ± 1.2</td></tr><tr><td>Motivational categories<sup>b</sup></td><td>55 for all</td><td></td></tr><tr><td> Intrinsic TM</td><td></td><td>2.7 ± 0.9</td></tr><tr><td> Identified TM</td><td></td><td>3.2 ± 0.7</td></tr><tr><td> Introjected TM</td><td></td><td>0.7 ± 0.8</td></tr><tr><td> External TM</td><td></td><td>1.5 ± 1.0</td></tr><tr><td> T Amotivation</td><td></td><td>0.9 ± 0.9</td></tr><tr><td>Teaching self-efficacy<sup>b</sup></td><td>55</td><td>2.5 ± 0.5</td></tr><tr><td>Situational variables<sup>b</sup></td><td>94 for all</td><td></td></tr><tr><td> Enough time to prepare lesson</td><td></td><td>2.1 ± 1.2</td></tr><tr><td> Stress before lesson</td><td></td><td>2.2 ± 1.1</td></tr><tr><td> Perceived students’ motivation</td><td></td><td>3.1 ± 0.7</td></tr><tr><td> Perceived students’ competences</td><td></td><td>2.9 ± 0.8</td></tr><tr><td> Perceived students’ respect</td><td></td><td>3.6 ± 0.6</td></tr></table> |
d0d24094639ef39b5d083c97682f5e65160a0ddd710e2242eb09a520bb539798.png | simple | <table><tr><td>Variant</td><td>Minor/major allele</td><td>Minor allele frequency</td></tr><tr><td>Genotyped and imputed</td><td> </td><td> </td></tr><tr><td>rs2206593</td><td>T/C</td><td>0.074</td></tr><tr><td>rs5275</td><td>C/T</td><td>0.317</td></tr><tr><td>rs10911905</td><td>G/T</td><td>0.084</td></tr><tr><td>rs2143417</td><td>T/G</td><td>0.100</td></tr><tr><td>Imputed</td><td> </td><td> </td></tr><tr><td>rs4648304</td><td>T/C</td><td>0.009</td></tr><tr><td>rs689470</td><td>T/C</td><td>0.016</td></tr><tr><td>rs2066826</td><td>A/G</td><td>0.077</td></tr><tr><td>rs5277</td><td>C/G</td><td>0.174</td></tr><tr><td>rs4648262</td><td>T/G</td><td>0.0001</td></tr><tr><td>rs4648261</td><td>A/G</td><td>0.069</td></tr><tr><td>rs2745557</td><td>T/C</td><td>0.174</td></tr><tr><td>rs20417</td><td>C/G</td><td>0.100</td></tr><tr><td>rs689466</td><td>G/A</td><td>0.205</td></tr><tr><td>rs689462</td><td>C/A</td><td>0.016</td></tr><tr><td>rs12042763</td><td>A/C</td><td>0.287</td></tr><tr><td>rs2745559</td><td>T/G</td><td>0.174</td></tr><tr><td>rs11583191</td><td>T/C</td><td>0.081</td></tr><tr><td>rs2143416</td><td>G/T</td><td>0.111</td></tr><tr><td>rs2179555</td><td>G/A</td><td>0.088</td></tr></table> |
c02a053b9c9f2591ed87282ca742d2ce2f5a37bb25a521623e4c40016daaaff4.png | complex | <table><tr><td>Medical</td><td>Nursing</td></tr><tr><td><i>Enhanced scopes of practice</i></td><td></td></tr><tr><td>• Physicians are allowed to private practice with specific fees during off hours</td><td>• Nurses also are allowed to work in the private sector before and after office hours</td></tr><tr><td><i>Producing new types of health workers</i></td><td></td></tr><tr><td>• The programmes for production of other paramedics such as medical assistants, laboratory assistants, pharmacists, and physiotherapy assistants are already in place</td><td>• Currently, there are a number of nursing and related programmes, such as BSc nursing, postbasic nursing, diploma in nursing, family welfare assistant, community skilled birth assistants, and community health-care providers</td></tr><tr><td><i>Compulsory service in rural area</i></td><td></td></tr><tr><td>• Provision of minimum 2 years of services at Union Health Sub-Centre</td><td>• The Nursing Personnel Recruitment Rules were developed in 1985, without any provision of compulsory rural services</td></tr><tr><td>• Preference to fill vacancies for remote and hard-to-reach areas/health facilities</td><td rowspan="2">• Recently, efforts are underway to introduce provision of compulsory services in rural health facilities</td></tr><tr><td>• Provision of non-practicing allowance is given to encourage physicians to purely focus on public services</td></tr><tr><td><i>Subsidized education for return of service</i></td><td></td></tr><tr><td>• Provision of scholarships, bursaries, and other training and education subsidies are available, but not particularly focused on rural retention</td><td>• Provision of scholarships, bursaries, and other training and education subsidies are available, but not particularly focused on rural retention</td></tr></table> |
e2d7a08636562c3b059be24b17e940dadfd366383b829c68d4c5580a2d3cdfbc.png | complex | <table><tr><td colspan="2">Hyphal size (μm)</td></tr><tr><td>Strain</td><td>Abscence of CE** vs. Presence of CE**</td></tr><tr><td>ATCC 90028</td><td>24.68 (24.68 ± 1.79) vs. 13.35 (13.35 ± 0.92)*</td></tr><tr><td>SC5314</td><td>30 (30 ± 2.47) vs. 16 (16 ± 1.16)*</td></tr><tr><td>Strain 01</td><td>21.67 (21.67 ± 1.39) vs. 15.02 (15.02 ± 1. 28)*</td></tr><tr><td>Strain 05</td><td>22.84 (22.84 ± 1.68) vs. 18.17 (18.17 ± 2.12)</td></tr><tr><td>Strain 06</td><td>19.3 (19.3 ± 1.23) vs. 11.24 (11.24 ± 1.79)*</td></tr><tr><td>Strain 12</td><td>10.16 (10.3 ± 1.89) vs. 16.62 (16.62 ± 1.34)</td></tr><tr><td>Strain 23</td><td>16.81 (16.81 ± 2.12) vs. 11.08 (11.08 ± 0,76)</td></tr><tr><td>Strain 30</td><td>10.06 (10.06 ± 0.86) vs. 14.32 (14.32 ± 0.97)</td></tr><tr><td>Strain 37</td><td>23.21 (23.21 ± 1.83) vs. 18.55 (18.55 ± 1. 48)*</td></tr><tr><td>Strain 40</td><td>23.28 (23.28 ± 1.94) vs. 13.6 (13.6 ± 0.91)*</td></tr><tr><td>Strain 54</td><td>15.35 (15.35 ± 1.41) vs. 3 (3 ± 0.32)*</td></tr><tr><td>Strain 10Li</td><td>21.25 (21.25 ± 1.87) vs. 11.73 (11.73 ± 0.92)*</td></tr><tr><td>Strain 111R</td><td>36.15 (36.15 ± 2.56) vs. 25.06 (25.06 ± 1.34)*</td></tr></table> |
be1af8a9d5b7cd17867b77ae3079b5fcb48a04132a73776592637de51d7d7c90.png | complex | <table><tr><td></td><td colspan="3">W</td><td colspan="3">AS</td><td>Vigilance state effect</td><td>Period effect</td></tr><tr><td>Period</td><td><i>control</i></td><td><i>prior</i></td><td><i>during</i></td><td><i>control</i></td><td><i>prior</i></td><td><i>during</i></td><td colspan="2"><i>P</i></td></tr><tr><td>Total V, s<sup>2</sup></td><td>0.069±0.069</td><td>0.055±0.058</td><td>0.074±0.068</td><td>0.054±0.061</td><td>0.050±0.052</td><td>0.056±0.059</td><td>0.008</td><td>0.060</td></tr><tr><td>LF, s<sup>2</sup></td><td>0.026±0.024</td><td>0.021±0.020</td><td>0.027±0.023</td><td>0.021±0.021</td><td>0.020±0.020</td><td>0.022±0.022</td><td>0.016</td><td>NS</td></tr><tr><td>HF, s<sup>2</sup></td><td>0.028±0.038</td><td>0.018±0.031</td><td>0.028±0.037</td><td>0019±0.031</td><td>0014±0.023</td><td>0016±0.026</td><td><0.001</td><td>0.025</td></tr><tr><td>LF<sub>nu</sub></td><td>62 ±19</td><td>68 ±21</td><td>63 ±20</td><td>65±20</td><td>70±19</td><td>68 ±20</td><td>0.030</td><td>0.024</td></tr><tr><td>HF<sub>nu</sub></td><td>38 ±19</td><td>32 ±21</td><td>37 ±20</td><td>35±20</td><td>30±19</td><td>32 ±20</td><td>0.030</td><td>0.024</td></tr><tr><td>LF/HF</td><td>3.2±3.5</td><td>4.2±4.3</td><td>3.3±3.5</td><td>3.7±4.4</td><td>4.9±5.3</td><td>4.9±6.5</td><td>0.007</td><td>0.045</td></tr></table> |
5b673f4ecbd778b9f40f2d74c310f91406bd06c95938093d2fb490fcf089fad3.png | complex | <table><tr><td>Objection</td><td>Primer</td><td>Sequences</td></tr><tr><td rowspan="2">Murine variable regions of the heavy chain (V<sub>H</sub>)</td><td>VHF</td><td>5'-GCTGCCCAACCAGCCATGGCCGAGGTGCAGCTGGTGGAATCGGG-3'</td></tr><tr><td>VHR</td><td>5'-CGATGGGCCCTTGGTGGAGGCTGCAGAGACAGTGACCAGAGT-3'</td></tr><tr><td rowspan="2">Murine variable regions of the light chain (V<sub>L</sub>)</td><td>VkF</td><td>5'-GGGCCCAGGCGGCCGAGCTCGATATTTTGCTCACTCAG-3'</td></tr><tr><td>VkR</td><td>5'-GAAGACAGATGGTGCAGCCACAGTTCGTTTCATTTCCAGTTTGGTCCC-3'</td></tr><tr><td rowspan="2">Human constant regions of the heavy chain domain 1 (C<sub>H</sub>1)</td><td>CH1-F</td><td>5'-GCCTCCACCAAGGGCCCATCGGTC-3'</td></tr><tr><td>dpseq</td><td>5'-GATATCAGAAGCGTAGTCCGGAACGTC-3'</td></tr><tr><td rowspan="2">Human constant regions of the light chain domain (C<sub>L</sub>)</td><td>HKC-F</td><td>5'-CGAACTGTGGCTGCACCATCTGTC-3'</td></tr><tr><td>Lead B</td><td>5'-AAGCTTGGCCATGGCTGGTTGGGCAGC-3'</td></tr><tr><td rowspan="2">Chimeric heavy chain (Fd)</td><td>Lead H</td><td>5'-CATATGGCTGCCCAACCAGCCATGGCC-3'</td></tr><tr><td>dpseq</td><td>Ditto</td></tr><tr><td rowspan="2">Chimeric light chain</td><td>RSF-F</td><td>5'-GGATCCGGAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3'</td></tr><tr><td>Lead B</td><td>Ditto</td></tr></table> |
2fccd9407b51d11639f580792bcc8d7d5d35fbb9feca3f144d2371a1f458007b.png | complex | <table><tr><td></td><td></td><td>Number of participants (% within category)</td></tr><tr><td rowspan="2">Country of graduation and current workplace</td><td>Rwanda</td><td>13 (76%)</td></tr><tr><td>Democratic Republic of the Congo</td><td>4 (24%)</td></tr><tr><td rowspan="3">Completed whole years since graduation</td><td>1 year</td><td>6 (35%)</td></tr><tr><td>2–3 years</td><td>6 (35%)</td></tr><tr><td>≥ 4 years</td><td>5 (29%)</td></tr><tr><td rowspan="2">Gender</td><td>Male</td><td>15 (88%)</td></tr><tr><td>Female</td><td>2 (12%)</td></tr><tr><td rowspan="4">Desired future specialty</td><td>General surgery</td><td>12 (71%)</td></tr><tr><td>Neurosurgery</td><td>2 (12%)</td></tr><tr><td>Orthopaedics</td><td>1 (6%)</td></tr><tr><td>Urology</td><td>2 (12%)</td></tr></table> |
0b6b71a2ae46f5953fe9ceb3a3861cf2968bc65d55244dcc0d63c9de3cc8c97d.png | complex | <table><tr><td>Characteristics</td><td>N</td><td>Total (%)</td><td>Boys (%)</td><td>Girls (%)</td><td>χ<sup>2</sup></td><td><i>p</i>-value</td></tr><tr><td>Sexually active</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>113</td><td>27.2</td><td>33.8</td><td>21.3</td><td rowspan="2">8.29</td><td rowspan="2">0.004</td></tr><tr><td>No</td><td>303</td><td>72.8</td><td>66.2</td><td>78.7</td></tr><tr><td>Early sex debut *</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Before 15 years</td><td>55</td><td>48.7</td><td>60.6</td><td>31.9</td><td rowspan="2">9.05</td><td rowspan="2">0.003</td></tr><tr><td>After 15 years</td><td>58</td><td>51.3</td><td>39.4</td><td>68.1</td></tr><tr><td>Multiple partner *</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>One</td><td>59</td><td>57.8</td><td>50</td><td>68.2</td><td rowspan="2">3.39</td><td rowspan="2">0.07</td></tr><tr><td>More than one</td><td>43</td><td>42.2</td><td>50</td><td>31.8</td></tr><tr><td>Condom use for last sexual intercourse *</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>57</td><td>53.3</td><td>50.8</td><td>41.3</td><td rowspan="2">0.95</td><td rowspan="2">0.33</td></tr><tr><td>No</td><td>50</td><td>46.7</td><td>49.2</td><td>58.7</td></tr><tr><td>Regular condom use *</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Irregular</td><td>53</td><td>55.2</td><td>52.8</td><td>58.1</td><td rowspan="2">0.27</td><td rowspan="2">0.60</td></tr><tr><td>Always</td><td>43</td><td>44.8</td><td>47.2</td><td>41.9</td></tr><tr><td>HIV testing *</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>54</td><td>13</td><td>13.4</td><td>12.7</td><td rowspan="2">0.04</td><td rowspan="2">0.84</td></tr><tr><td>No</td><td>360</td><td>87</td><td>86.6</td><td>87.3</td></tr></table> |
f52ff2db1ac57253dec1dd9bd9deb3e095ba5c40e249640ed6d3479eecc53d17.png | simple | <table><tr><td>Parameters</td><td>Patients with T1DM(n = 162)</td><td>controls(n = 80)</td><td><i>P</i>- value</td></tr><tr><td>Age (years)</td><td>19.35 ± 2.6</td><td>19.76 ± 2.76</td><td>0.3</td></tr><tr><td>Females (%)</td><td>55.5% (90/162)</td><td>55% (44/80)</td><td>0.93</td></tr><tr><td>Gastrointestinal symptoms</td><td>4.3% (7/162)</td><td>3.7% (3/80)</td><td>0.83</td></tr><tr><td>Duration of diabetes (years)</td><td>7.29 ± 7.9</td><td>_</td><td></td></tr><tr><td>HbA1c (%)</td><td>8.2 ± 1.75</td><td>_</td><td></td></tr></table> |
323bc4148ab84c602a11500c093019f7d42a05b3ee2ad737d238ad309a4d3c69.png | complex | <table><tr><td>CME activity</td><td>Activity 2</td><td>Activity 3</td></tr><tr><td>Sample size</td><td>n=1237</td><td>n=611</td></tr><tr><td colspan="3">Responses to: Practitioners are asked to report drug adverse events:</td></tr><tr><td colspan="3">A. To MedWatch</td></tr><tr><td colspan="3">B. Only when the adverse event is not specified on the drug label</td></tr><tr><td colspan="3">C. Within 30 days of occurrence, as required by law.</td></tr><tr><td colspan="3">D. Voluntarily, if observed within 30 days of the first dose</td></tr><tr><td>Correct (A)</td><td>698 (56%)</td><td>237 (39%)</td></tr><tr><td>Incorrect (B)</td><td>85 (7%)</td><td>53 (9%)</td></tr><tr><td>Incorrect (C)</td><td>203 (10%)</td><td>174 (29%)</td></tr><tr><td>Incorrect (D)</td><td>243 (20%)</td><td>146 (24%)</td></tr><tr><td>Correct vs. Predicted</td><td>−14%</td><td>−31%</td></tr></table> |
a9b71a95ab93d0829cbe6ac85314bb28540f66fa3eb0c036ff82570f9920df7a.png | complex | <table><tr><td>Presyn</td><td>Postsyn</td><td>Type</td><td>Conv</td><td>Div</td><td># Synapses</td></tr><tr><td>MF</td><td>Glom</td><td>Excitatory</td><td>1</td><td>20</td><td>5000</td></tr><tr><td>Glom</td><td>GR</td><td>Excitatory</td><td>4</td><td>53</td><td>262,400</td></tr><tr><td>Glom</td><td>GO</td><td>Excitatory</td><td>40</td><td>0.77</td><td>4000</td></tr><tr><td>GO</td><td>GR</td><td>Inhibitory</td><td>3.23</td><td>2120</td><td>212,000</td></tr><tr><td>GR</td><td>GO</td><td>Excitatory</td><td>2000</td><td>3</td><td>200,000</td></tr><tr><td><i>GR</i></td><td><i>PC</i></td><td><i>Excitatory</i></td><td><i>65,600</i></td><td><i>400</i></td><td><i>26,240,000</i></td></tr><tr><td>IO</td><td>PC</td><td>Teaching</td><td>1</td><td>10</td><td>400</td></tr><tr><td><i>PC</i></td><td><i>DCN</i></td><td><i>Inhibitory</i></td><td><i>40</i></td><td><i>5</i></td><td><i>2,000</i></td></tr><tr><td>DCN (30%)</td><td>IO</td><td>Inhibitory</td><td>0.34</td><td>1</td><td>14</td></tr><tr><td>IO</td><td>DCN</td><td>Excitatory</td><td>1</td><td>1,41</td><td>50</td></tr><tr><td><i>MF</i></td><td><i>DCN</i></td><td><i>Excitatory</i></td><td><i>12</i></td><td><i>2.4</i></td><td><i>600</i></td></tr><tr><td colspan="5">Total number of synapses</td><td>26,926,464</td></tr></table> |
89f96d4d758de4c43f8e043b9e1e4f9b3dc77b0694c13cf2ca02a13ab3e832c0.png | simple | <table><tr><td>Transporters</td><td>Organism</td><td>Cells/Tissue</td><td>Cargo (proteins) specific to each importin or exportin</td><td>Reference</td></tr><tr><td>Importin <i>α</i>1</td><td>Human</td><td>ROS 17/2.8, UMR-106, MC3T3-E1, and SaOS-2</td><td>Type 1 parathyroid hormone receptor</td><td>[62]</td></tr><tr><td>Importin <i>α</i>2</td><td>Human</td><td>HuT-78 cells</td><td>GATA-3</td><td>[63]</td></tr><tr><td>Importin <i>α</i>3</td><td>Human</td><td>A5A9 lung cells, human Bronchial smooth muscle cells</td><td>NF-<i>κ</i>B p50/p65</td><td>[25, 50]</td></tr><tr><td>Importin <i>α</i>3</td><td>Mouse</td><td>Mouse lung tissue</td><td>NF-<i>κ</i>B p65</td><td>[11]</td></tr><tr><td>Importin <i>α</i>4</td><td>Human</td><td>A5A9 lung cells</td><td>NF-<i>κ</i>B p50/p65</td><td>[25]</td></tr><tr><td>Importin <i>α</i>5</td><td>Human</td><td>COS-1HepG2HuH7 hepatoma cells</td><td>STAT3 STAT1-STAT2</td><td>[45] [43]</td></tr><tr><td>Importin <i>β</i>1</td><td>Human</td><td>HEK293HUVECC58CO57HeLa</td><td>PRPF31NF-<i>κ</i>BCREBPTHrPSRY/SOX-9Cyclin B1NFAT</td><td>[64–69][33][68]</td></tr><tr><td>Importin <i>β</i>1</td><td>Mouse</td><td>Sf9</td><td>NFAT</td><td>[69]</td></tr><tr><td>Importin <i>β</i>2</td><td>Human</td><td>HeLa</td><td>HPV16E6 oncoprotein</td><td>[70]</td></tr><tr><td>Importin <i>β</i>3</td><td>Human</td><td>HeLa</td><td>c-JunRibosomal proteins</td><td>[71, 72]</td></tr><tr><td>Importin 4</td><td>Human</td><td>HeLa</td><td>Vitamin D receptorHIF1-<i>α</i></td><td>[73, 74]</td></tr><tr><td>Importin 5</td><td>Human</td><td>HeLa</td><td>c-Jun</td><td>[70]</td></tr><tr><td>Importin 7</td><td>Human</td><td>HeLa</td><td>c-JunHistone H1CREBSMAD3Glucocorticoid receptor</td><td>[71][75, 76][33][48][55]</td></tr><tr><td>Importin 8</td><td>Human</td><td>HaCaTCOS-1</td><td>SMADsSignal recognition particle protein 19</td><td>[76, 77]</td></tr><tr><td>Importin 9</td><td>Human</td><td>HeLa</td><td>c-JunPP2A (PR65)</td><td>[71][78]</td></tr><tr><td>Importin 11</td><td>Human</td><td>BHK</td><td>L12UbcM2</td><td>[79, 80]</td></tr><tr><td>Importin 13</td><td>Human</td><td>HeLaAirway epithelial cells</td><td>c-JunGlucocorticoid receptor</td><td>[71] [57]</td></tr><tr><td>Importin <i>α</i>/<i>β</i></td><td>Human</td><td>HTCMCF-7</td><td>HIV-1 integraseP53</td><td>[81, 82]</td></tr><tr><td>Exportin 1</td><td>Human</td><td>NIH-3H3HeLa</td><td>Cyclin D1I<i>κ</i>BNFAT</td><td>[14, 26, 83, 84]</td></tr><tr><td>Exportin 4</td><td>Mouse</td><td>HeLa</td><td>elF-5A</td><td>[15]</td></tr><tr><td>Exportin 5</td><td>Human</td><td>BHK</td><td>Staufen2</td><td>[85]</td></tr><tr><td>Exportin 6</td><td>Human</td><td> </td><td>Actin</td><td>[86]</td></tr><tr><td>Exportin 7</td><td>Human</td><td>HeLaBHK</td><td>P50RhoGAP</td><td>[87]</td></tr><tr><td>Exportin t</td><td>Human</td><td>HeLa</td><td>tRNA</td><td>[72, 88]</td></tr></table> |
09eecd839f30445fe510bbd5e7097c845d907884e5f6db96edbe99346a098d1b.png | complex | <table><tr><td></td><td></td><td>Total (N = 2,984)</td><td colspan="3">Healthcare care utilization in the past 12 months (<i>n</i> = 1,978)</td><td colspan="3">Any marital violence in the past 12 months (<i>n</i> = 834)</td></tr><tr><td></td><td></td><td>%<sup>a</sup></td><td>Prevalence %<sup>b</sup></td><td>Χ<sup>2</sup> (DF)</td><td><i>p</i> value</td><td>Prevalence %<sup>b</sup></td><td>Χ<sup>2</sup> (DF)</td><td><i>p</i> value</td></tr><tr><td rowspan="2">Health care</td><td>Utilized</td><td>66.3</td><td></td><td></td><td></td><td>29.3</td><td>5.10 (1)</td><td>0.024<sup>*</sup></td></tr><tr><td>Not utilized</td><td>33.7</td><td></td><td></td><td></td><td>25.4</td><td></td><td></td></tr><tr><td rowspan="2">Marital violence</td><td>Any</td><td>28.0</td><td>69.4</td><td>5.10 (1)</td><td>0.024<sup>*</sup></td><td></td><td></td><td></td></tr><tr><td>None</td><td>72.1</td><td>65.1</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="3">Education</td><td>Jr. high/high</td><td>27.0</td><td>62.4</td><td>13.56 (2)</td><td>0.001<sup>*</sup></td><td>29.7</td><td>2.34 (2)</td><td>0.310</td></tr><tr><td>College</td><td>31.3</td><td>64.7</td><td></td><td></td><td>28.6</td><td></td><td></td></tr><tr><td>University</td><td>41.7</td><td>69.9</td><td></td><td></td><td>26.7</td><td></td><td></td></tr><tr><td rowspan="3">Household income</td><td>Low</td><td>26.5</td><td>60.7</td><td>23.73 (2)</td><td><0.001<sup>*</sup></td><td>30.8</td><td>5.36 (2)</td><td>0.068</td></tr><tr><td>Average</td><td>36.9</td><td>66.5</td><td></td><td></td><td>29.5</td><td></td><td></td></tr><tr><td>High</td><td>36.6</td><td>72.4</td><td></td><td></td><td>25.8</td><td></td><td></td></tr><tr><td rowspan="2">Employment</td><td>Employed</td><td>77.9</td><td>66.8</td><td>1.38 (1)</td><td>0.239</td><td>27.1</td><td>3.18 (1)</td><td>0.075</td></tr><tr><td>Not-employed</td><td>22.1</td><td>64.3</td><td></td><td></td><td>30.7</td><td></td><td></td></tr><tr><td rowspan="2">Gender</td><td>Men</td><td>44.0</td><td>64.3</td><td>4.54 (1)</td><td>0.033<sup>*</sup></td><td>28.3</td><td>0.05 (1)</td><td>0.818</td></tr><tr><td>Women</td><td>56.0</td><td>68.0</td><td></td><td></td><td>27.9</td><td></td><td></td></tr></table> |
3ae7f0b10352db97420a8667b0d8722358ada5afae5a7daa0813ad315af6b325.png | complex | <table><tr><td rowspan="2">Characteristics (n)</td><td colspan="3">DR5</td><td colspan="3">DR4</td></tr><tr><td>+ (%)</td><td>−(%)</td><td>P-value</td><td>+ (%)</td><td>−(%)</td><td>P-value</td></tr><tr><td>Age (yr)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> ≤40 (n=59)</td><td>21(35.6)</td><td>38(64.4)</td><td></td><td>17(28.8)</td><td>42(71.2)</td><td></td></tr><tr><td> >40 (n=115)</td><td>42(36.5)</td><td>73(63.5)</td><td>0.904</td><td>35(30.4)</td><td>80(69.6)</td><td>0.825</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Female (n=38)</td><td>13 (34.2)</td><td>25(65.8)</td><td></td><td>13(34.2)</td><td>25(65.8)</td><td></td></tr><tr><td> Male (n=136)</td><td>50 (36.8)</td><td>86 (63.2)</td><td>0.772</td><td>39(28.7)</td><td>97(71.3)</td><td>0.510</td></tr><tr><td>Histological type</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> DNC (n=14)</td><td>5(35.7)</td><td>9(64.3)</td><td></td><td>4(28.6)</td><td>10(71.4)</td><td></td></tr><tr><td> UDNC (n=160)</td><td>58(36.3)</td><td>102(63.8)</td><td>0.968</td><td>48(30.0)</td><td>112(70.0)</td><td>0.911</td></tr><tr><td>Clinical stages</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Stages I-II (n=72)</td><td>34(47.2)</td><td>38(52.8)</td><td></td><td>21(29.2)</td><td>51(70.8)</td><td></td></tr><tr><td> Stages III-IV (n=102)</td><td>29(28.4)</td><td>73(71.6)</td><td>0.011</td><td>31(30.4)</td><td>71(69.6)</td><td>0.862</td></tr><tr><td>LN status</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> LNM (n=124)</td><td>36(29.0)</td><td>88(71.0)</td><td></td><td>37(29.8)</td><td>87(70.2)</td><td></td></tr><tr><td> No LNM (n=50)</td><td>27(54.0)</td><td>23(46.0)</td><td>0.002</td><td>15(30.0)</td><td>35(70.0)</td><td>0.983</td></tr><tr><td>Survival status</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Alive (n=111)</td><td>49(44.1)</td><td>62(55.9)</td><td></td><td>36(32.4)</td><td>75(67.6)</td><td></td></tr><tr><td> Dead (n=63)</td><td>14(22.2)</td><td>49(77.8)</td><td>0.004</td><td>16(25.4)</td><td>47(74.6)</td><td>0.330</td></tr></table> |
41bd071b8a871b4a0adecfd08800b470bb1c8e0fee8a46beb49f6046585ef5f4.png | simple | <table><tr><td>Viruses</td><td>F1140O2-5 VP3</td><td>F11VP2O-2 VP2</td><td>F12VP1O-2 Site 1b</td><td>F21-48 Site 1a,5</td><td>F21-64 Site 1a,5</td><td>F21-34 Site 2</td><td>F21-58 Site 2</td><td>F21-41 Site 3</td><td>F21-18 Near site 4</td></tr><tr><td>ECU/4/2010</td><td>0.10</td><td>1.07</td><td>0.49</td><td>1.42</td><td>0.45</td><td>-0.004</td><td>0.014</td><td>1.76</td><td>0.014</td></tr><tr><td>HKN/2/2011</td><td>1.21</td><td>-0.02</td><td>1.12</td><td>0.25</td><td>0.98</td><td>0.05</td><td>0.02</td><td>1.36</td><td>0.05</td></tr><tr><td>VIT/32/11</td><td>1.22</td><td>1.02</td><td>0.56</td><td>1.51</td><td>1.52</td><td>0.15</td><td>0.04</td><td>1.44</td><td>1.39</td></tr><tr><td>AFG/41/11</td><td>1.13</td><td>1.03</td><td>0.65</td><td>1.17</td><td>1.20</td><td>1.11</td><td>1.19</td><td>0.28</td><td>0.12</td></tr><tr><td>ETH/39/2009</td><td>1.20</td><td>1.05</td><td>0.39</td><td>1.2</td><td>1.2</td><td>1.15</td><td>1.19</td><td>1.10</td><td>1.05</td></tr><tr><td>UAE/9/2009</td><td>1.30</td><td>1.03</td><td>0.83</td><td>1.39</td><td>1.41</td><td>0.95</td><td>1.36</td><td>1.33</td><td>0.76</td></tr><tr><td>IRN/11/2006</td><td>1.07</td><td>1.02</td><td>0.49</td><td>1.13</td><td>1.10</td><td>0.99</td><td>1.10</td><td>1.08</td><td>1.06</td></tr><tr><td>TAW/12/98</td><td>1.58</td><td>0.80</td><td>0.06</td><td>1.57</td><td>1.63</td><td>1.55</td><td>1.61</td><td>0.07</td><td>-0.02</td></tr><tr><td>KUW/1/11</td><td>1.26</td><td>1.08</td><td>0.33</td><td>1.30</td><td>1.31</td><td>1.25</td><td>1.25</td><td>0.90</td><td>0.73</td></tr></table> |
7dce2dba7c15c8b1eba72f89d1dc3287bdc13c5c093edae689cbbd590fa4f190.png | complex | <table><tr><td>Maternal Infection Status</td><td>Incidence rate per 100 pyrs (95% CI)</td><td>Cox HR (95% CI)</td><td>Adjusted HR<sup>a</sup> (95% CI)</td><td><i>P</i> Value</td><td>Adjusted HR<sup>b</sup> (95% CI)</td><td><i>P</i> Value</td></tr><tr><td colspan="7">No malaria</td></tr><tr><td> No hookworm</td><td>28.81 (27.33,30.38)</td><td>1</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td> Hookworm</td><td>37.93 (35.95,40.01)</td><td>1.31 (1.15–1.50)</td><td>1.20 (1.05–1.38)</td><td>.01</td><td>1.17 (1.03–1.34)</td><td>.02</td></tr><tr><td colspan="7">Had malaria</td></tr><tr><td> No hookworm</td><td>35.09 (29.96,41.09)</td><td>1</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td> Hookworm</td><td>52.46 (46.48,59.21)</td><td>1.48 (1.03–2.14)</td><td>1.63 (1.15–2.32)</td><td>.01</td><td>1.60 (1.13–2.26)</td><td>.01</td></tr><tr><td colspan="7"><i>P</i><sub>interaction</sub> = .23<sup>c</sup></td></tr><tr><td colspan="7">No malaria</td></tr><tr><td> No <i>Mansonella perstans</i></td><td>30.79 (29.49,32.15)</td><td>1</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td> <i>M. perstans</i></td><td>40.05 (37.13,43.21)</td><td>1.30 (1.12–1.51)</td><td>1.26 (1.08–1.46)</td><td>.003</td><td>1.21 (1.03–1.40)</td><td>.02</td></tr><tr><td colspan="7">Had malaria</td></tr><tr><td> No <i>M. perstans</i></td><td>44.33 (39.35,49.93)</td><td>1</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td> <i>M. perstans</i></td><td>44.34 (37.68,52.18)</td><td>0.99 (.70–1.40)</td><td>1.25 (.87–1.79)</td><td>.23</td><td>1.22 (.85–1.76)</td><td>.28</td></tr><tr><td colspan="7"><i>P</i><sub>interaction</sub> = .32<sup>c</sup></td></tr><tr><td colspan="7">No malaria</td></tr><tr><td> No <i>Schistosoma mansoni</i></td><td>31.85 (30.53,33.22)</td><td>1</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td> <i>S. mansoni</i></td><td>36.41 (33.52,39,54)</td><td>1.14 (.96–1.36)</td><td>1.10 (.92–1.31)</td><td>.29</td><td>1.09 (.92–1.29)</td><td>.33</td></tr><tr><td colspan="7">Had malaria</td></tr><tr><td> No <i>S. mansoni</i></td><td>43.91 (39.49,48.83)</td><td>1</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td> <i>S. mansoni</i></td><td>46.36 (36.97,58.14)</td><td>1.06 (.61–1.86)</td><td>0.86 (.53–1.41)</td><td>.56</td><td>0.88 (.53–1.44)</td><td>.60</td></tr><tr><td colspan="7"><i>P</i><sub>interaction</sub> = .50<sup>c</sup></td></tr></table> |
374b0f745be97fc0c822a282edc757c53fe90c783c14dd3a533f9ef2f8af60be.png | simple | <table><tr><td>Video</td><td>CT</td><td>DFT</td><td>ORIA</td><td>MTT</td><td>ASLA</td><td>L1APG</td><td>SCM</td><td>MIL</td><td>MCT</td></tr><tr><td><i>Basketball</i></td><td>0.278</td><td>0.604</td><td>0.072</td><td>0.223</td><td>0.398</td><td>0.256</td><td>0.475</td><td>0.247</td><td>0.526</td></tr><tr><td><i>Boy</i></td><td>0.587</td><td>0.418</td><td>0.189</td><td>0.502</td><td>0.389</td><td>0.725</td><td>0.397</td><td>0.491</td><td>0.818</td></tr><tr><td><i>Football</i></td><td>0.607</td><td>0.651</td><td>0.513</td><td>0.575</td><td>0.533</td><td>0.553</td><td>0.489</td><td>0.585</td><td>0.580</td></tr><tr><td><i>Jogging-1</i></td><td>0.212</td><td>0.218</td><td>0.221</td><td>0.211</td><td>0.213</td><td>0.208</td><td>0.212</td><td>0.214</td><td>0.717</td></tr><tr><td><i>Skating1</i></td><td>0.123</td><td>0.172</td><td>0.242</td><td>0.144</td><td>0.501</td><td>0.143</td><td>0.471</td><td>0.161</td><td>0.487</td></tr><tr><td><i>Girl</i></td><td>0.318</td><td>0.293</td><td>0.263</td><td>0.657</td><td>0.701</td><td>0.719</td><td>0.673</td><td>0.403</td><td>0.880</td></tr><tr><td><i>Coke</i></td><td>0.241</td><td>0.142</td><td>0.215</td><td>0.449</td><td>0.192</td><td>0.203</td><td>0.342</td><td>0.224</td><td>0.539</td></tr><tr><td><i>Sylvester</i></td><td>0.658</td><td>0.391</td><td>0.642</td><td>0.641</td><td>0.590</td><td>0.413</td><td>0.677</td><td>0.528</td><td>0.659</td></tr><tr><td>Average</td><td>0.378</td><td>0.361</td><td>0.295</td><td>0.425</td><td>0.440</td><td>0.403</td><td>0.467</td><td>0.357</td><td>0.650</td></tr></table> |
8d4bd9f3f098b24a42358454140ef1bd6e479b32862351611f72d2a94b71407f.png | simple | <table><tr><td>Metric</td><td>Target Performance</td></tr><tr><td>HC</td><td>Communication latency and energy consumption reduction (indirectly)</td></tr><tr><td>ETX</td><td>Reduction of required frame retransmissions</td></tr><tr><td>RE</td><td>Expansion of network lifetime</td></tr><tr><td>PFI</td><td>Reduction of network-layer losses</td></tr><tr><td>ETT</td><td>Assignment of weights to the individual links</td></tr><tr><td>WCETT</td><td>Focus on fixed nodes of local networks</td></tr></table> |
2c8547b73196b03e83afd5c0fe765440be0bb330fda433cc8e16bdc4d5283379.png | complex | <table><tr><td>Variable</td><td>Perc. difference (with - without OB)</td><td>Difference (with - without OB)</td><td>t-stats</td></tr><tr><td>Hourly Revenue (Eur)</td><td>15.4</td><td>6.9</td><td>2.76</td></tr><tr><td>Waiting time (Min)</td><td>3.66</td><td>6.2</td><td>0.34</td></tr><tr><td>Idle time (Min)</td><td>−1.42</td><td>−9.1</td><td>−1.33</td></tr><tr><td>Overtime (Min)</td><td>4.05</td><td>10</td><td>0.3</td></tr><tr><td colspan="2">Number of days with OB</td><td>112</td><td></td></tr><tr><td colspan="2">of days without OB</td><td>62</td><td></td></tr></table> |
cef2d7fad89a606e7d2b826e1c6b5571fb45d2fdf0875985a88a2a0421bae66f.png | simple | <table><tr><td>Task</td><td>Search</td><td>Share</td><td>Read</td><td>Repeat</td><td>Comp man</td><td>Comp auto</td><td>Query</td><td>Analyse</td><td>Browse</td><td>Populate</td></tr><tr><td>Importance</td><td>Low</td><td>Med</td><td>Med</td><td>High</td><td>Low</td><td>High</td><td>Low</td><td>Low</td><td>Low</td><td>Med</td></tr></table> |
da2ca70c07c0aaf8df891e125312d02b396471d90ef5355e10f08970efa8708d.png | complex | <table><tr><td> </td><td colspan="3">Proteinuria negative (<i>n</i> = 13)</td><td colspan="3">Proteinuria positive (<i>n</i> = 67)</td><td rowspan="2"><i>p</i> value</td></tr><tr><td> </td><td>Median</td><td>(min–max)</td><td>IQR</td><td>Median</td><td>(min–max)</td><td>IQR</td></tr><tr><td><sup>*</sup>Systolic blood pressure</td><td>117</td><td>103–136</td><td>20</td><td>126</td><td>95–184</td><td>16</td><td>0,11</td></tr><tr><td><sup>*</sup>Diastolic blood pressure</td><td>77</td><td>64–94</td><td>10</td><td>74</td><td>57–98</td><td>10</td><td>0,13</td></tr><tr><td><sup>*</sup>Pulse pressure </td><td>41</td><td>26–51</td><td>9</td><td>52</td><td>32–78</td><td>13</td><td>0,01</td></tr><tr><td><sup>*</sup>Mean aortic pressure</td><td>100</td><td>73–120</td><td>13,5</td><td>100</td><td>70–133</td><td>17</td><td>0,24</td></tr><tr><td>Aortic distensibility</td><td>2,93</td><td>1,56–14,40</td><td>3,70</td><td>2,44</td><td>0,32–11,20</td><td>1,98</td><td>0,14</td></tr><tr><td>Aortic systolic diameter (mm)</td><td>30,61</td><td>26,55–38,31</td><td>5,60</td><td>33,11</td><td>25,81–48,16</td><td>6,30</td><td>0,01</td></tr><tr><td>Aortic diastolic diameter (mm)</td><td>29,18</td><td>26,10–37,71</td><td>5,84</td><td>32,78</td><td>25,46–47,06</td><td>6,62</td><td>0,008</td></tr></table> |
e71846bbbbd965fe5df5660d56606908e2e189e4f071302571db634808371af9.png | complex | <table><tr><td>Feeding model*</td><td colspan="3">Time of measurement</td><td>Reference</td></tr><tr><td></td><td>2 h</td><td>4, 5, or 6 h</td><td>24 h</td><td></td></tr><tr><td colspan="5">MCH-INDUCED HYPERPHAGIA IN RAT</td></tr><tr><td>Male Sprague-Dawley</td><td></td><td>−90%</td><td></td><td>Takekawa et al. (2002)</td></tr><tr><td>Male Sprague-Dawley</td><td>−72%</td><td></td><td></td><td>Moriya et al. (2009)</td></tr><tr><td>Male Sprague-Dawley</td><td>−75%</td><td>−75%</td><td></td><td>Nagasaki et al. (2009)</td></tr><tr><td>Male Wistar</td><td>−70%</td><td></td><td></td><td>Borowsky et al. (2002)</td></tr><tr><td colspan="5">FASTING-INDUCED FEEDING</td></tr><tr><td>Male Wistar rats</td><td>−35%</td><td>−30%</td><td>−25%</td><td>Huang et al. (2005)</td></tr><tr><td>Mice (strain and gender unknown)</td><td>−80%</td><td>−40%</td><td></td><td>Balavoine et al. (2007)</td></tr><tr><td>DIO male C57BL/6NCrl:BR mice</td><td>−35%</td><td>−32%</td><td>−22%</td><td>McBriar et al. (2006)</td></tr><tr><td>DIO mice (strain and gender unknown)</td><td></td><td>−17%</td><td>−14%</td><td>Palani et al. (2005)</td></tr><tr><td>DIO mice (strain and gender unknown)</td><td>−12%</td><td>−20%</td><td>−9%</td><td>Sasikumar et al. (2006)</td></tr><tr><td colspan="5">SPONTANEOUS FEEDING</td></tr><tr><td>Male Sprague-Dawley rats</td><td></td><td></td><td>−30%</td><td>Kamata et al. (2011)</td></tr><tr><td>Female KK<i>Ay</i> mice</td><td>−63%</td><td></td><td></td><td>Kamata et al. (2011)</td></tr><tr><td>DIO C57BL/6J mice (gender unknown)</td><td></td><td></td><td>−19%</td><td>Haga et al. (2011)</td></tr><tr><td>DIO mice (strain and gender unknown)</td><td></td><td></td><td>−21%</td><td>Xu et al. (2006)</td></tr><tr><td>DIO male F344/Jcl rats</td><td></td><td></td><td>−30%</td><td>Kasai et al. (2012)</td></tr><tr><td>DIO male F344/Jcl rats</td><td></td><td>−28%</td><td></td><td>Kasai et al. (2011)</td></tr><tr><td>DIO male Sprague-Dawley rats</td><td></td><td></td><td>−31%</td><td>Kowalski and Sasikumar (2007)</td></tr><tr><td>Male Sprague-Dawley rats, ingestion of condensed milk<sup>#</sup></td><td>−45%</td><td></td><td></td><td>Borowsky et al. (2002)</td></tr></table> |
2993354125a0bd6321bc154402a11a6f0bd09bbcc9dd535d42d93ec6462ee9c4.png | complex | <table><tr><td></td><td>50–59 yrs</td><td>60-69 yrs</td><td><i>≥</i>70 yrs</td></tr><tr><td>Patients</td><td>1310</td><td>1180</td><td>726</td></tr><tr><td colspan="4">Cases of vertebral fracture</td></tr><tr><td> n, (%)</td><td>31(2.37%)#△</td><td>105(8.90%)*△</td><td>159(21.90%)*#</td></tr></table> |
b1dbc8fe91dcde17d52462dccff79a36dca9ff1113dfc3b7f722f90811edc711.png | simple | <table><tr><td></td><td>Number of ACT</td><td>% first-line treatment</td></tr><tr><td>Benin</td><td>95</td><td>83.2</td></tr><tr><td>DRC</td><td>131</td><td>67.9</td></tr><tr><td>Madagascar</td><td>83</td><td>76.9</td></tr><tr><td>Nigeria</td><td>171</td><td>88.1</td></tr><tr><td>Uganda</td><td>360</td><td>100.0</td></tr><tr><td>Zambia</td><td>380</td><td>99.5</td></tr></table> |
ed729d7f102d875b67629de748edeb6be78ccd8628e0013d727e4dd5d6c03017.png | simple | <table><tr><td></td><td>Bone 1</td><td>Bone 2</td><td>Bone 3</td><td>Bone 4</td><td>Bone 5</td><td>Bone 6</td><td>Bone 7</td></tr><tr><td>Bone 1</td><td>-</td><td>NS</td><td>NS</td><td>NS</td><td>S</td><td>NS</td><td>NS</td></tr><tr><td>Bone 2</td><td>NS</td><td>-</td><td>NS</td><td>NS</td><td>S</td><td>NS</td><td>NS</td></tr><tr><td>Bone 3</td><td>NS</td><td>NS</td><td>-</td><td>NS</td><td>S</td><td>NS</td><td>NS</td></tr><tr><td>Bone 4</td><td>NS</td><td>NS</td><td>NS</td><td>-</td><td>NS</td><td>NS</td><td>NS</td></tr><tr><td>Bone 5</td><td>S</td><td>S</td><td>S</td><td>NS</td><td>-</td><td>S</td><td>NS</td></tr><tr><td>Bone 6</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>S</td><td>-</td><td>NS</td></tr><tr><td>Bone 7</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>-</td></tr></table> |
ddb986aaffc629f08a3ba37a38d6cb1c46a52e9ce619395f7978a1a038202d73.png | simple | <table><tr><td></td><td>All patients (n = 146)</td><td>QoL group (n = 81)</td></tr><tr><td>Age [years]</td><td>44 (13 - 74)</td><td>46 (16-74)</td></tr><tr><td>Gender ratio (male : female)</td><td>37 (25.3%) : 109 (74.7%)</td><td>16 (19.8%) : 65 (80.2%)</td></tr><tr><td>Tumor size [mm]</td><td>65 (10 - 230)</td><td>70 (8 - 230)</td></tr><tr><td>Preoperative bilirubine level [mg/dl]</td><td>0.5 (0.2 - 6.2)</td><td>0.5 (0.2 - 3.0)</td></tr><tr><td>Preoperative AST [U/l]</td><td>24 (6 - 259)</td><td>24 (8 - 259)</td></tr><tr><td>Preoperative ALT [U/l]</td><td>26 (4 - 775)</td><td>25 (5 - 775)</td></tr><tr><td>Preoperative Quick value [%]</td><td>97 (27 - 130)</td><td>98 (27 - 130)</td></tr></table> |
736d09472e29a3c384de067d9909d57bf2222d98c94f73da13c9f7d45a0b4025.png | complex | <table><tr><td>Variables</td><td>UC (<i>N</i> = 181)</td></tr><tr><td colspan="2">Sex</td></tr><tr><td> Male</td><td>107 (59.1%)</td></tr><tr><td>Age at UC diagnosis (years), median (IQR)</td><td>35.8 (26.1–47.8)</td></tr><tr><td>Age at FC level measurement (years), median (IQR)</td><td>40.5 (29.2–53.8)</td></tr><tr><td>Disease duration before FC level measurement (months), median (IQR)</td><td>18.4 (1.9–59.5)</td></tr><tr><td colspan="2">Maximum extent of UC</td></tr><tr><td> Proctitis</td><td>33 (18.2%)</td></tr><tr><td> Left-sided colitis</td><td>47 (26.0%)</td></tr><tr><td> Extensive colitis</td><td>101 (55.8%)</td></tr><tr><td colspan="2">Disease severity of UC</td></tr><tr><td> Clinical remission (Mayo score 0-2)</td><td>17 (9.4%)</td></tr><tr><td> Mild activity (Mayo score 3-5)</td><td>48 (26.5%)</td></tr><tr><td> Moderate activity (Mayo score 6-10)</td><td>98 (54.1%)</td></tr><tr><td> Severe activity (Mayo score 11-12)</td><td>18 (10.0%)</td></tr><tr><td colspan="2">Smoking status at UC diagnosis</td></tr><tr><td> Never smoker</td><td>100 (55.2%)</td></tr><tr><td> Former smoker</td><td>47 (26.0%)</td></tr><tr><td> Current smoker</td><td>34 (18.8%)</td></tr><tr><td colspan="2">Family history of IBD</td></tr><tr><td> No family history</td><td>171 (94.5%)</td></tr><tr><td> First-degree relative</td><td>9 (5.0%)</td></tr><tr><td> Second-degree relative</td><td>1 (0.5%)</td></tr><tr><td colspan="2">History of medication use at FC level measurement</td></tr><tr><td> Oral 5-ASA</td><td>154 (85.1%)</td></tr><tr><td> Topical 5-ASA</td><td>116 (64.1%)</td></tr><tr><td> Topical steroids</td><td>32 (17.7%)</td></tr><tr><td> Systemic corticosteroids</td><td>124 (68.5%)</td></tr><tr><td> Thiopurines</td><td>58 (32.0%)</td></tr><tr><td> Cyclosporine</td><td>4 (2.2%)</td></tr><tr><td> Anti-TNF agents</td><td>30 (16.6%)</td></tr><tr><td>FC level (mg/kg), median (IQR)</td><td>1518.0 (360.0–4205.0)</td></tr><tr><td>Hematocrit value (%), median (IQR)</td><td>37.7 (32.8–42.0)</td></tr><tr><td>Serum albumin level (g/dL), median (IQR)</td><td>3.7 (2.9–4.0)</td></tr><tr><td>Erythrocyte sedimentation rate (mm/h), median (IQR)</td><td>26.0 (11.5–44.5)</td></tr><tr><td>White blood cell count (×10<sup>3</sup> /uL), median (IQR)</td><td>7.1 (5.6–9.5)</td></tr><tr><td>Platelet count (×10<sup>3</sup> /uL), median (IQR)</td><td>300.0 (242.0–379.0)</td></tr><tr><td>C-reactive protein level (mg/L), median (IQR)</td><td>0.41 (0.10–2.37)</td></tr><tr><td>Partial Mayo score, median (IQR)</td><td>5 (2–6.5)</td></tr><tr><td>Mayo endoscopic subscore, median (IQR)</td><td>3 (2–3)</td></tr><tr><td>Mayo score, median (IQR)</td><td>6 (3–8)</td></tr><tr><td>UCEIS, median (IQR)</td><td>4 (3–6)</td></tr></table> |
91415fc249621457b773a585d495834e7d76ffde0e1dca3281f7426a4f801ffb.png | simple | <table><tr><td>Authors (year), country</td><td>Participants</td><td>Tool (cut-off if provided)</td><td>Results</td></tr><tr><td>Burch et al. (2008) [63], South AfricaRisk of bias: High</td><td>790</td><td>MEWS</td><td>Hospital admissionMEWS 0–2 (ref)MEWS 3–4: RR 1.3 (95% CI 1.1 to 1.6)MEWS ≥5: RR 1.7 (95% CI 1.5 to 2.0)In-hospital mortalityMEWS 0–2 (ref)MEWS 3–4: RR 2.8 (95% CI 1.7 to 4.8)MEWS ≥5: RR 4.6 (95% CI 2.7 to 7.8)</td></tr><tr><td>Correia et al. (2014) [55], PortugalRisk of bias: Unclear</td><td>65</td><td>EWS</td><td>Length of hospital stay & MortalityScore at 24 h and 12 h seemed to predict both length of stay and mortality (<i>p</i> < 0.05). The EWS would have increased early medical attention by 40% if a threshold of ≥3 was used.</td></tr><tr><td>Dundar et al. (2015) [41], TurkeyRisk of bias: Low</td><td>671</td><td>MEWSVIEWS</td><td>HospitalisationMEWS (≥3): AUROC 0.73 (95% CI 0.69–0.77)VIEWS (≥6): AUROC 0.76 (95% CI 0.72–0.79)In-hospital mortalityMEWS (≥4): AUROC 0.89 (95% CI 0.84–0.94)VIEWS (≥8): AUROC 0.90 (95% CI 0.86–0.94)</td></tr><tr><td>Eick et al. (2015) [42], GermanyRisk of bias: Low</td><td>5730</td><td>MEWS</td><td>In-hospital mortalityAUROC: 0.71 (0.67–0.75; <i>p</i> < 0.001)</td></tr><tr><td>Graham et al. (2007) [56], Hong KongRisk of bias: Unclear (Conference abstract)</td><td>413</td><td>MEWS (>4)</td><td>In-hospital mortalityOR 8.3 (95% CI 1.1–60.4), <i>p</i> = 0.013ED re-attendance within 48 hOR 45.2 (95% CI 3.4–568.9), <i>p</i> < 0.0001</td></tr><tr><td>Heitz et al. (2010) [43], USARisk of bias: Low</td><td>280</td><td>MEWS Max (≥4)MEWS plus</td><td>Need for higher level of care or mortality within 24 hMEWS Max: AUROC 0.73 (95% CI, 0.66–0.79)MEWS Plus: AUROC 0.76 (95% CI, 0.69–0.82)</td></tr><tr><td>Junhasavasdiku et al. (2012) [58], ThailandRisk of bias: Unclear</td><td>381</td><td>MEWS</td><td>MortalityMEWS at ED was associated with mortality (<i>p</i> < 0.001)</td></tr><tr><td>Naidoo et al. (2014) [62], South AfricaRisk of bias: High</td><td>265</td><td>TEWS</td><td>Discharge within 24 h of admission, admission to a ward, admission to an intensive care unit (ICU), and death in hospital.TEWS <7: 53.7% discharged; no admitted to ICU; none died.TEWS ≥7: 18.7% discharged; 3 admitted to ICU; 4 died</td></tr><tr><td>Olsson et al. (2003) [33], SwedenRisk of bias: Low</td><td>1027</td><td>APACHE IIRAPSREMS</td><td>MortalityREMS: AUROC: 0.91 ± 0.02RAPS: AUROC: 0.87 ± 0.02APACHE II: AUROC: 0.90 ± 0.02</td></tr><tr><td>Olsson et al. (2004) [34], SwedenRisk of bias: Low</td><td>11,751</td><td>RAPSREMS</td><td>MortalityRAPS: AUROC: 0.65 ± 0.02REMS: AUROC: 0.85 ± 0.01</td></tr><tr><td>Subbe et al. (2006) [50], UKRisk of bias: Low</td><td>(a) 53 unselected; (b): 49 ICU admission; (c): 49 ED admission, transferred to ward then ICU</td><td>MEWS (>2)ASSIST (>3)MET (=1)MTS (orange or red)</td><td>Patients identified as critically ill (at risk of deterioration)MTS: Sensitivity: (a) 15%; (b) 96%; (c) 65%MEWS: Sensitivity (a): 8%; (b) 77%; (c) 55%ASSIST: Sensitivity (a): 0%; (b) 22%; (c) 16%MET: Sensitivity (a) 0%; (b) 2%; (c) 7%</td></tr><tr><td>Wang et al. (2016) [60], TaiwanRisk of bias: Unclear</td><td>99</td><td>CCIMEWS</td><td>Survival to dischargeCCI: Adjusted OR 0.57 (95% CI 0.38–0.84); <i>p</i> = 0.005Peri-arrest MEWS: Adjusted OR 0.77 (95% CI 0.60–0.97); <i>p</i> = 0.028</td></tr></table> |
c89c0882cc4a3b75cccb151c84cf099d267aba476017109a5894b65e9fe326a8.png | simple | <table><tr><td>Models (Prevent/Treatment)</td><td>Antioxidant/Plants</td><td>Effects</td><td>Dose (Dose-Effect)</td><td>Bioactive Compounds</td><td>References</td></tr><tr><td>Diabetic rats fed on a high fat thermolyzed diet (Prevent)</td><td>Omega 3-polyunsaturated fatty acids</td><td>↑ SOD, CAT; ↓ triglycerides, non-esterified fatty acid, lipoperoxidation</td><td>3.0% in diet</td><td>Omega 3-polyunsaturated fatty acids</td><td>[108]</td></tr><tr><td>Mice fed with high-fat diet (Prevent and treatment)</td><td><i>Moringa oleifera</i> leaves; haw pectic oligosaccharide; <i>Thymbra spicata</i></td><td>↑ GSH; ↓ ALT, AST, ALP, lipid peroxidation</td><td>50, 150 and 300 mg/kg b.w. (No dose–effect)</td><td>Haw pectic oligosaccharide</td><td>[109,110,111]</td></tr><tr><td>Liver damage in diet-induced atherosclerotic rats (Prevent)</td><td><i>Tulbaghia violacea</i> rhizomes</td><td>↓ LDH, AST, ALT, ALP, bilirubin antioxidation</td><td>100 mg/kg b.w.</td><td></td><td>[112]</td></tr><tr><td>Rabbits with high-fat diet (Prevent)</td><td>Apolipoprotein A–I</td><td>↑ SOD, GSH-Px; ↓ iNOS, MDA</td><td>15 mg/kg b.w.</td><td></td><td>[113]</td></tr><tr><td>WeRats fed a high-fat diet (Prevent)</td><td>Black cabbage sprout</td><td>↑ SOD, CAT, NADPH, GSH-Px, GRD GST</td><td>250 and 500 mg/kg b.w. (Dose–effect)</td><td></td><td>[114]</td></tr></table> |
0adcb9f3927b740150be8331a5824d54c0a845ed3509f3fb8655c68fb0871ad2.png | complex | <table><tr><td></td><td colspan="3">Before The Establishment of Trauma Team</td><td colspan="3">After The Establishment of Trauma Team</td><td></td><td></td></tr><tr><td></td><td>n</td><td>Average</td><td>SD</td><td>n</td><td>Average</td><td>SD</td><td>t</td><td>p</td></tr><tr><td>ICU stay</td><td>47</td><td>7.81</td><td>7.96</td><td>76</td><td>8.74</td><td>8.98</td><td>−.581</td><td>0.562</td></tr><tr><td>LOS</td><td>63</td><td>22.16</td><td>14.80</td><td>131</td><td>19.63</td><td>15.58</td><td>1.074</td><td>0.284</td></tr><tr><td>Operation waiting time</td><td>17</td><td>37.47</td><td>19.71</td><td>16</td><td>33.75</td><td>58.20</td><td>.249</td><td>0.805</td></tr><tr><td>Duration stay in ER</td><td>17</td><td>290.65</td><td>353.06</td><td>16</td><td>180.75</td><td>141.35</td><td>1.160</td><td>0.255</td></tr><tr><td>Clinical Charge</td><td>63</td><td>9976.56</td><td>7433.79</td><td>131</td><td>8627.64</td><td>7289.05</td><td>1.199</td><td>0.232</td></tr><tr><td>Ward Charge</td><td>63</td><td>52,786.79</td><td>54,062.83</td><td>131</td><td>43,025.78</td><td>51,620.02</td><td>1.214</td><td>0.226</td></tr><tr><td>Examination Charge</td><td>62</td><td>15,666.29</td><td>21,999.81</td><td>124</td><td>10,545.89</td><td>13,254.21</td><td>1.975</td><td>0.05*</td></tr><tr><td>Radiology Charge</td><td>62</td><td>8864.85</td><td>9071.37</td><td>124</td><td>5638.11</td><td>8396.92</td><td>2.398</td><td>0.018*</td></tr><tr><td>Procedure Charge</td><td>63</td><td>23,629.67</td><td>27,658.80</td><td>131</td><td>21,331.63</td><td>33,887.60</td><td>.468</td><td>0.640</td></tr><tr><td>Operation Charge</td><td>42</td><td>54,561.48</td><td>41,418.76</td><td>88</td><td>41,394.32</td><td>34,149.59</td><td>1.916</td><td>0.05*</td></tr><tr><td>Total Medical Charge</td><td>63</td><td>224,411.86</td><td>227,087.79</td><td>131</td><td>172,125.21</td><td>192,091.67</td><td>1.671</td><td>0.096</td></tr></table> |
a88592075193858ca2c6e55fd046401aefe0fdccecafec6e72503acbca6edb14.png | complex | <table><tr><td>Questions for nurse practitioners</td><td>Questions for senior doctors and nurses</td></tr><tr><td>1. How would you describe your role?</td><td>1. What is your understanding of the role of the NP?</td></tr><tr><td>2. How is the role of a Nurse Practitioner (NP) different from that of doctors and other nurses?</td><td>2. What do you perceive is the impact of the NP role on the delivery of care?</td></tr><tr><td>− What is the impact of the NP on the delivery of care?</td><td>3. How do you think the role of the NP influences the roles of doctors and nurses?</td></tr><tr><td>3. Do you think that the roles of existing Emergency Department (ED) clinicians have changed as a result of the NP role?</td><td>4. What are the mechanisms that determine the role of the NP?</td></tr><tr><td>4. Do you think the roles of NPs would differ at other sites?</td><td rowspan="2">5. What is your view on the overlap between NP roles and those of doctors?</td></tr><tr><td>− Why do you think they would differ? (e.g. due to ICT, casemix, culture etc.)</td></tr><tr><td>− What are the mechanisms which determine the role of the NP? For example, what factors lead to these differences across sites?</td><td> </td></tr><tr><td>5. What is your view on the overlap between NP roles and those of doctors?</td><td> </td></tr></table> |
1595724d2a791abf035bd527e976a6cea9b6176278e7c56186eb6a2c2a7399a0.png | complex | <table><tr><td rowspan="2">Variables (mm)</td><td rowspan="2"></td><td colspan="3">Δ(T2 − T1)</td></tr><tr><td>Mean</td><td>SD</td><td><i>p</i> value</td></tr><tr><td></td><td>UP(y) (mm)</td><td>−1.24</td><td>1.84</td><td>0.049*</td></tr><tr><td></td><td>Stm(y) (mm)</td><td>0.63</td><td>1.17</td><td>0.103</td></tr><tr><td></td><td>Stm(z) (mm)</td><td>−1.79</td><td>2.48</td><td>0.003**</td></tr><tr><td></td><td>LP(y (mm))</td><td>−2.1</td><td>1.54</td><td>0.001**</td></tr><tr><td></td><td>LP(z) (mm)</td><td>−2.7</td><td>3.44</td><td>0.025*</td></tr><tr><td></td><td>Li(z) (mm)</td><td>−4.32</td><td>2.49</td><td>0.000**</td></tr><tr><td>1</td><td>Sn-Ls-UP (°)</td><td>−3.16</td><td>11.21</td><td>0.371</td></tr><tr><td>2</td><td>Ls-UP-Stm (°)</td><td>−9.36</td><td>10.75</td><td>0.016*</td></tr><tr><td>3</td><td>Stm-LP-Li (°)</td><td>6.43</td><td>10.29</td><td>0.065*</td></tr><tr><td>4</td><td>LP-Li-Ln (°)</td><td>5.19</td><td>12.59</td><td>0.201</td></tr></table> |
2aee90421f644aec35529b761277de8300b178e68696fedf0549a5f42d9d2cc0.png | complex | <table><tr><td>Demographic characteristics</td><td>Consented to biobanking (<i>n</i> = 2,100)</td><td>Refused or withdrew (<i>n</i> = 75)</td><td><i>p</i>-Value</td></tr><tr><td>Father’s age; mean (SD)</td><td>39.1 (38.8–39.5)</td><td>41.3 (39.6–42.9)</td><td>0.034</td></tr><tr><td>Mother’s age; mean (SD)</td><td>33.1 (32.9–33.5)</td><td>34.8 (33.1–36.5)</td><td>0.056</td></tr><tr><td colspan="4">Mother’s level of education</td><td colspan="4"></td><td colspan="4"></td></tr><tr><td>Before or finished primary school</td><td>468 (22.3%)</td><td>7 (9.3%)</td><td rowspan="3">0.0001</td></tr><tr><td>Finished preparatory, secondary, or technical school</td><td>912 (43.4%)</td><td>23 (30.7%)</td></tr><tr><td>Education higher than high school</td><td>720 (34.3%)</td><td>45 (60%)</td></tr><tr><td colspan="4">Father’s level of education</td><td colspan="4"></td><td colspan="4"></td></tr><tr><td>Before or finished primary school</td><td>411 (19.6%)</td><td>5 (6.8%)</td><td rowspan="3">0.001</td></tr><tr><td>Finished preparatory, secondary, or technical school</td><td>948 (4.1%)</td><td>24 (32.9%)</td></tr><tr><td>Education higher than high school</td><td>741 (35.3%)</td><td>44 (60.3%)</td></tr><tr><td colspan="4">Residency</td><td colspan="4"></td><td colspan="4"></td></tr><tr><td>Metropolitan Cairo</td><td>818 (39%)</td><td>35 (46.7%)</td><td rowspan="6">0.5</td></tr><tr><td>Lower Egypt and Delta (except coastal governorates)</td><td>598 (28.5%)</td><td>18 (24%)</td></tr><tr><td>Coastal governorates</td><td>289 (13.8%)</td><td>11 (14.7%)</td></tr><tr><td>Upper Egypt</td><td>255 (12.1%)</td><td>5 (6.7%)</td></tr><tr><td>Suez Canal</td><td>78 (3.7%)</td><td>4 (5.3%)</td></tr><tr><td>Outside Egypt</td><td>62 (3%)</td><td>2 (4.3%)</td></tr><tr><td colspan="4">Population distribution</td><td colspan="4"></td><td colspan="4"></td></tr><tr><td>Rural</td><td>817 (38.9%)</td><td>22 (27.7%)</td><td rowspan="2">0.077</td></tr><tr><td>Urban</td><td>1,283 (61.1%)</td><td>53 (70.7%)</td></tr></table> |
8a92658a03d340d28a4e1a2141484221ab23b5badd4239a5a078ac58079704ac.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Splenic aspirate parasitologic result</td><td rowspan="2">Total</td></tr><tr><td>Negative</td><td>Positive</td></tr><tr><td colspan="4">rK39 ICT strip test</td></tr><tr><td> Negative</td><td>5</td><td>7</td><td>12</td></tr><tr><td> Positive</td><td>13</td><td>37</td><td>50</td></tr><tr><td>Total</td><td>18</td><td>44</td><td>62</td></tr></table> |
aff02633178c7209b4098ffae0ed9e22300a30502e7f927668c87351fca8d57a.png | complex | <table><tr><td></td><td colspan="3"># of Patients (%)</td></tr><tr><td>Characteristic</td><td>Female</td><td>Male</td><td>P Value</td></tr><tr><td>Age (yrs) (n = 86)</td><td></td><td></td><td>0.26</td></tr><tr><td> <60</td><td>37 (88.1%)</td><td>42 (95.5%)</td><td></td></tr><tr><td> >/=60</td><td>5 (11.9%)</td><td>2 (4.5%)</td><td></td></tr><tr><td>Ethnicity (n = 87)</td><td></td><td></td><td>0.19</td></tr><tr><td> Hispanic</td><td>23 (53.5%)</td><td>30 (68.2%)</td><td></td></tr><tr><td> Non-Hispanic</td><td>20 (46.5%)</td><td>14 (31.8%)</td><td></td></tr><tr><td>Hemoglobin (g/dL) (n = 83)</td><td></td><td></td><td>0.019</td></tr><tr><td> <12</td><td>34 (80.9%)</td><td>23 (56.1%)</td><td></td></tr><tr><td> >/=12</td><td>8 (19.1%)</td><td>18(43.9%)</td><td></td></tr><tr><td>Leukocyte count (× 10<sup>9</sup>/L) (n = 85)</td><td></td><td></td><td>0.46</td></tr><tr><td> <50</td><td>13 (30.2%)</td><td>9 (21.4%)</td><td></td></tr><tr><td> >/=50</td><td>30 (69.8%)</td><td>33 (78.6%)</td><td></td></tr><tr><td>Platelets (× 10<sup>9</sup>/L) (n = 82)</td><td></td><td></td><td>0.041</td></tr><tr><td> <450</td><td>20 (48.8%)</td><td>30 (73.2%)</td><td></td></tr><tr><td> >/=450</td><td>21 (51.2%)</td><td>11 (26.8%)</td><td></td></tr><tr><td>Hasford Score (n = 64)</td><td></td><td></td><td>1</td></tr><tr><td> </=780 low-risk</td><td>19 (52.8%)</td><td>16 (57.1%)</td><td></td></tr><tr><td> >780 and </=1480 intermediate</td><td>12 (33.3%)</td><td>9 (32.1%)</td><td></td></tr><tr><td> >1480 high-risk</td><td>5 (13.9%)</td><td>3 (10.7%)</td><td></td></tr><tr><td>Sokal Score (n = 65)</td><td></td><td></td><td>0.39</td></tr><tr><td> <0.8 good prognosis</td><td>12 (33.3%)</td><td>13 (44.8%)</td><td></td></tr><tr><td> 0.8–1.2 moderate prognosis</td><td>16 (44.4%)</td><td>8 (27.6%)</td><td></td></tr><tr><td> >1.2 poor prognosis</td><td>8 (22.2%)</td><td>8 (27.6%)</td><td></td></tr><tr><td>CHR at 3 months, all treatments (n = 47)</td><td></td><td></td><td>0.23</td></tr><tr><td> Yes</td><td>13 (50%)</td><td>15 (71.4%)</td><td></td></tr><tr><td> No</td><td>13 (50%)</td><td>6 (28.6%)</td><td></td></tr><tr><td>CHR at 3 months, imatinib only (n = 36)</td><td></td><td></td><td>0.13</td></tr><tr><td> Yes</td><td>12 (63.2%)</td><td>15 (88.2%)</td><td></td></tr><tr><td> No</td><td>7 (38.4%)</td><td>2 (11.8%)</td><td></td></tr></table> |
be62be40b467a787aff53d60f51c6e8c2a1f836cb8463054b34e085375d11b21.png | simple | <table><tr><td> </td><td>Category</td><td>No. of cases</td><td>Meandensity of TFPI-2 Mean± SD</td><td>Statistics value</td><td>p value</td></tr><tr><td>Age</td><td>≤55</td><td>74</td><td>0.324±0.061</td><td>t=0.302</td><td>0.764</td></tr><tr><td> </td><td>>55</td><td>47</td><td>0.327±0.052</td><td> </td><td> </td></tr><tr><td>Tumor size</td><td>≤2 cm</td><td>56</td><td>0.351±0.061</td><td>t=4.948</td><td>0.001</td></tr><tr><td> </td><td>>2 cm</td><td>65</td><td>0.303±0.044</td><td> </td><td> </td></tr><tr><td>Skin involvement<sup>a</sup></td><td>No</td><td>96</td><td>0.336±0.057</td><td>t=4.252</td><td>0.001</td></tr><tr><td> </td><td>Yes</td><td>25</td><td>0.284±0.038</td><td> </td><td> </td></tr><tr><td>LN metastasis</td><td>0</td><td>70</td><td>0.348±0.055</td><td>F=12.896<sup>b</sup></td><td>0.001</td></tr><tr><td> </td><td>1-3</td><td>22</td><td>0.292±0.043</td><td> </td><td> </td></tr><tr><td> </td><td>4-9</td><td>15</td><td>0.316±0.048</td><td> </td><td> </td></tr><tr><td> </td><td>10-</td><td>13</td><td>0.272±0.038</td><td> </td><td> </td></tr><tr><td> </td><td>Unknown</td><td>1</td><td> </td><td> </td><td> </td></tr><tr><td>Histologic grade</td><td>≤II</td><td>71</td><td>0.339±0.057</td><td>t=3.389</td><td>0.001</td></tr><tr><td> </td><td>>II</td><td>50</td><td>0.305±0.052</td><td> </td><td> </td></tr><tr><td>Vessel invasion</td><td>Absence</td><td>109</td><td>0.333±0.054</td><td>t=5.172</td><td>0.001</td></tr><tr><td> </td><td>Presence</td><td>12</td><td>0.251±0.030</td><td> </td><td> </td></tr><tr><td>Clinical stage<sup>c</sup></td><td>I</td><td>35</td><td>0.375±0.053</td><td>Chi-Square=43.867<sup>c</sup></td><td>0.001</td></tr><tr><td> </td><td>II</td><td>52</td><td>0.317±0.048</td><td> </td><td> </td></tr><tr><td> </td><td>III</td><td>34</td><td>0.286±0.034</td><td> </td><td> </td></tr><tr><td>ER</td><td>(-)</td><td>43</td><td>0.327±0.055</td><td>t=0.253</td><td>0.801</td></tr><tr><td> </td><td>(+)</td><td>77</td><td>0.324±0.059</td><td> </td><td> </td></tr><tr><td> </td><td>Unknown</td><td>1</td><td> </td><td> </td><td> </td></tr><tr><td>PR</td><td>(-)</td><td>63</td><td>0.319±0.055</td><td>t=-1.211</td><td>0.228</td></tr><tr><td> </td><td>(+)</td><td>57</td><td>0.332±0.060</td><td> </td><td> </td></tr><tr><td> </td><td>Unknown</td><td>1</td><td> </td><td> </td><td> </td></tr><tr><td>HER-2</td><td>(-)</td><td>62</td><td>0.333±0.059</td><td>t=1.361</td><td>0.176</td></tr><tr><td> </td><td>(+)</td><td>55</td><td>0.318±0.056</td><td> </td><td> </td></tr><tr><td> </td><td>Unknown</td><td>4</td><td> </td><td> </td><td> </td></tr><tr><td>Tumor type</td><td>IDC<sup>d</sup></td><td>98</td><td>0.324±0.057</td><td>t=0.488</td><td>0.626</td></tr><tr><td> </td><td>Non-IDC<sup>e</sup></td><td>23</td><td>0.330±0.059</td><td> </td><td> </td></tr></table> |
c2763945454fa5fb18de7a1ffd8bda3a5ea38bd153b15d199573281eeedade06.png | complex | <table><tr><td rowspan="2"><i>var</i> gene type<sup>a</sup></td><td rowspan="2">Genome</td><td rowspan="2">Geographic origin</td><td colspan="2">Binding phenotype</td><td colspan="2">No. of potential thrombin cleavage sites by<sup>b</sup>:</td><td colspan="2">No. of potential thrombin cleavage sites with sequence<sup>b</sup>:</td><td colspan="3">Presence of<sup>c</sup>:</td><td rowspan="2">Thrombin cleavage</td></tr><tr><td>CIDR1</td><td>Other</td><td>Prosper</td><td>Peptide Cutter</td><td>PR</td><td>PRXXR</td><td>DBLδ1</td><td>KPRGPA</td><td>GLGRSL</td></tr><tr><td>IT4var06 (DC8)</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>EPCR</td><td>?</td><td>0</td><td>11</td><td>7</td><td>1<sup>d</sup></td><td>Yes</td><td>No</td><td>No</td><td>ND<sup>e</sup></td></tr><tr><td>IT4var19 (DC8)</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>EPCR</td><td>?</td><td>0</td><td>0</td><td>7</td><td>1<sup>d</sup></td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>IT4var20 (DC8)</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>EPCR</td><td>?</td><td>0</td><td>1</td><td>7</td><td>0</td><td>Yes</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>IT4var32b (DC8)</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>EPCR</td><td>?</td><td>0</td><td>0</td><td>7</td><td>1<sup>d</sup></td><td>Yes</td><td>Yes</td><td>Yes</td><td>ND</td></tr><tr><td>DD2var47 (DC8)</td><td>DD2</td><td>Southeast Asia</td><td>EPCR</td><td>?</td><td>0</td><td>1</td><td>6</td><td>0</td><td>Yes</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>IGHvar19 (DC8)</td><td>IGH</td><td>India</td><td>EPCR</td><td>?</td><td>0</td><td>0</td><td>6</td><td>1<sup>d</sup></td><td>Yes</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>RAJ116var08 (DC8)</td><td>RAJ116</td><td>India</td><td>EPCR</td><td>?</td><td>0</td><td>0</td><td>4</td><td>0</td><td>No</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>PFCLINvar30 (DC8)</td><td>PFCLIN</td><td>Africa</td><td>EPCR</td><td>?</td><td>0</td><td>0</td><td>4</td><td>0</td><td>No</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>PFD0020c (DC8)</td><td>3D7</td><td>Unknown</td><td>EPCR</td><td>?</td><td>0</td><td>2</td><td>10</td><td>2 (1<sup>d</sup>)</td><td>Yes</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>PF08_0140 (DC8)</td><td>3D7</td><td>Unknown</td><td>EPCR</td><td>?</td><td>1</td><td>1</td><td>7</td><td>0</td><td>Yes</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>RAJ116var11 (DC8)</td><td>RAJ116</td><td>India</td><td>EPCR</td><td>?</td><td>0</td><td>0</td><td>6</td><td>1<sup>d</sup></td><td>Yes</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>PFCLINvar31 (DC8)</td><td>PFCLIN</td><td>Africa</td><td>EPCR</td><td>?</td><td>2</td><td>1</td><td>6</td><td>1</td><td>No</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>MAL6P1.316 (DC8)</td><td>3D7</td><td>Unknown</td><td>EPCR</td><td>?</td><td>0</td><td>1</td><td>6</td><td>0</td><td>No</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>IT4var01</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>CD36</td><td>ICAM-1</td><td>0</td><td>1</td><td>3</td><td>0</td><td>No</td><td>No</td><td>No</td><td>No</td></tr><tr><td>IT4var11</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>CD36</td><td>?</td><td>0</td><td>0</td><td>3</td><td>1<sup>d</sup></td><td>Yes</td><td>No</td><td>No</td><td>Yes</td></tr><tr><td>IT4var14</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>CD36</td><td>ICAM-1</td><td>0</td><td>0</td><td>7</td><td>1<sup>d</sup></td><td>Yes</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>IT4var16</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>CD36</td><td>ICAM-1</td><td>1</td><td>2</td><td>4</td><td>1<sup>d</sup></td><td>Yes</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>IT4var31</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>CD36</td><td>ICAM-1</td><td>0</td><td>0</td><td>3</td><td>1</td><td>No</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>IT4var33</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>CD36</td><td>?</td><td>1</td><td>1</td><td>2</td><td>1<sup>d</sup></td><td>Yes</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>IT4var39</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>CD36</td><td>?</td><td>0</td><td>0</td><td>3</td><td>1<sup>d</sup></td><td>Yes</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>IT4var44</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>CD36</td><td>?</td><td>0</td><td>0</td><td>4</td><td>1<sup>d</sup></td><td>Yes</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>IT4var07</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>EPCR</td><td>ICAM-1</td><td>0</td><td>3</td><td>3</td><td>1<sup>d</sup></td><td>Yes</td><td>No</td><td>Yes</td><td>Yes</td></tr><tr><td>HB3var03</td><td>HB3</td><td>Central America</td><td>EPCR</td><td>ICAM-1</td><td>0</td><td>0</td><td>5</td><td>1</td><td>No</td><td>No</td><td>No</td><td>No</td></tr><tr><td>PFD1235wD4</td><td>3D7</td><td>Unknown</td><td>EPCR</td><td>ICAM-1</td><td>1</td><td>1</td><td>8</td><td>2 (1<sup>d</sup>)</td><td>Yes</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>IT4var02</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>?</td><td>PECAM-1</td><td>0</td><td>0</td><td>8</td><td>1</td><td>No</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>PF11_0008</td><td>3D7</td><td>Unknown</td><td>?</td><td>PECAM-1</td><td>0</td><td>0</td><td>8</td><td>1</td><td>No</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>PF13_0003</td><td>3D7</td><td>Unknown</td><td>?</td><td>Rosette</td><td>1</td><td>0</td><td>10</td><td>1</td><td>No</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>HB3var06</td><td>HB3</td><td>Central America</td><td>?</td><td>Rosette</td><td>0</td><td>0</td><td>6</td><td>0</td><td>No</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>IT4var09</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>EPCR</td><td>Rosette</td><td>0</td><td>0</td><td>4</td><td>1<sup>d</sup></td><td>Yes</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>IT4var60</td><td>IT4/FCR3</td><td>Southeast Asia</td><td>?</td><td>Rosette</td><td>1</td><td>0</td><td>6</td><td>0</td><td>No</td><td>No</td><td>No</td><td>ND</td></tr><tr><td>Total (<i>n</i> = 30)</td><td></td><td></td><td></td><td></td><td>8</td><td>26</td><td>170</td><td>23</td><td>18</td><td>2</td><td>3</td><td>3/5</td></tr></table> |
0f78daccc25112d57bf10499fada2c90f64e891bd2077ed73a1eb495ce389345.png | simple | <table><tr><td>Reference material (Certified or recommended values)</td><td>Matrix</td><td>Recovery rate</td></tr><tr><td>NIST 1643e (60.45±0.72 ppb)</td><td>Water</td><td>93 to 102%</td></tr><tr><td>NIST 1568a (290±30 ppb)</td><td>Poultry feed/Excreta</td><td>91 to 99%</td></tr><tr><td>Arsenic standard (20 ppb)</td><td>Egg</td><td>89 to 97%</td></tr></table> |
a02e16f90426187d41f8399979d622b2648094be5b9bafbb8fd03b20f614f579.png | simple | <table><tr><td> </td><td>Conventional group</td><td>Cocktail group</td><td>P</td></tr><tr><td>Mean dosage (mg) <sup>a</sup></td><td> </td><td> </td><td>N/A</td></tr><tr><td>- Meperidine</td><td>58.33 ± 24.46</td><td>25</td><td> </td></tr><tr><td>- Midazolam</td><td>6.81 ± 2.12</td><td>2.5</td><td> </td></tr><tr><td>- Propofol</td><td>0</td><td>172.08 ± 92.15</td><td> </td></tr><tr><td>Dosage (mg/kg/hr) <sup>a</sup></td><td> </td><td> </td><td>N/A</td></tr><tr><td>- Meperidine</td><td>2.42 ± 2.58</td><td>1.06 ± 0.60</td><td> </td></tr><tr><td>- Midazolam</td><td>0.29 ± 0.36</td><td>0.11 ± 0.06</td><td> </td></tr><tr><td>- Propofol</td><td>0</td><td>6.18 ± 3.0</td><td> </td></tr><tr><td>Indications for ERCP</td><td> </td><td> </td><td>0.621</td></tr><tr><td>- CBD stone</td><td>51 (50.0%)</td><td>53 (51.5%)</td><td> </td></tr><tr><td>- Benign biliary stricture</td><td>7 (6.9%)</td><td>10 (9.7%)</td><td> </td></tr><tr><td>- Malignant biliary stricture</td><td>28 (27.4%)</td><td>20 (19.4%)</td><td> </td></tr><tr><td>- Pancreatic therapy</td><td>5 (4.9%)</td><td>8 (7.8%)</td><td> </td></tr><tr><td>- Others</td><td>11 (10.8%)</td><td>12 (11.6)</td><td> </td></tr><tr><td>Time to intubation (min) <sup>a</sup></td><td>3.10 ± 1.86</td><td>3.68 ± 2.38</td><td>0.053</td></tr><tr><td>Duration (min) <sup>a</sup></td><td>31.60 ± 17.56</td><td>27.88 ±14.38</td><td>0.099</td></tr></table> |
8644c67fab9a905794708e172bb46195ee0f72145d3bcddf39f0db9f4d53ec66.png | simple | <table><tr><td>Construct</td><td>[NaCl]</td><td><i>K<sub>d</sub></i></td></tr><tr><td></td><td><i>mm</i></td><td><i>nm</i></td></tr><tr><td>N-domain</td><td>0</td><td>47.80 ± 4.94</td></tr><tr><td></td><td>20</td><td>4.61 ± 0.63</td></tr><tr><td>C-domain</td><td>0</td><td>45.50 ± 4.24</td></tr><tr><td></td><td>20</td><td>13.50 ± 2.06</td></tr><tr><td>R186H</td><td>0</td><td>132.00 ± 6.72</td></tr><tr><td></td><td>20</td><td>4.42 ± 0.50</td></tr><tr><td>E403R</td><td>0</td><td>2.67 ± 0.31</td></tr><tr><td></td><td>20</td><td>6.76 ± 0.65</td></tr><tr><td>R522Q</td><td>0</td><td>22.00 ± 3.31</td></tr><tr><td></td><td>20</td><td>15.90 ± 2.09</td></tr><tr><td>R522K</td><td>0</td><td>35.30 ± 2.85</td></tr><tr><td></td><td>20</td><td>26.30 ± 1.86</td></tr></table> |
2e3dece24f093342b704fafbb2134ddedd81e7d2db105473786fe708118dad2a.png | simple | <table><tr><td>Characteristics</td><td>Whole cohort (<i>n</i> = 5685)</td></tr><tr><td>Women (%)</td><td>2782 (50.6)</td></tr><tr><td>Age (years)</td><td>43.7 ± 0.4</td></tr><tr><td>Race/ethnicity (%)</td><td></td></tr><tr><td> Non-Hispanic whites</td><td>2898 (73.5)</td></tr><tr><td> Non-Hispanic blacks</td><td>1085 (9.4)</td></tr><tr><td> Mexican Americans</td><td>1021 (7.8)</td></tr><tr><td> Others</td><td>681 (9.3)</td></tr><tr><td>Education categories (%)</td><td></td></tr><tr><td> Below high school</td><td>1409 (16.1)</td></tr><tr><td> High school</td><td>1391 (24.3)</td></tr><tr><td> Above high school</td><td>2885 (59.5)</td></tr><tr><td>Smoking (%)</td><td></td></tr><tr><td> Never smoker</td><td>3045 (52.9)</td></tr><tr><td> Former smoker</td><td>1284 (22.9)</td></tr><tr><td> Current smoker</td><td>1356 (24.2)</td></tr><tr><td>Current drinker (%)</td><td>4056 (76.3)</td></tr><tr><td>Moderate physical activity (%)</td><td>2741 (54.9)</td></tr><tr><td>Body mass index (%)</td><td></td></tr><tr><td> Normal weight</td><td>1869 (35.2)</td></tr><tr><td> Overweight</td><td>2036 (34.6)</td></tr><tr><td> Obese</td><td>1780 (30.1)</td></tr><tr><td>Depression (%)</td><td>348 (5.0)</td></tr><tr><td>Systolic blood pressure (mm Hg)</td><td>119.7 ± 0.3</td></tr><tr><td>C-reactive protein (mg/dL)</td><td>0.358 ± 0.011</td></tr><tr><td>Total cholesterol (mg/dL)</td><td>200.74 ± 0.78</td></tr><tr><td>Prediabetes (%)</td><td>2058 (31.3)</td></tr></table> |
7d780019bcf95929e588f51bcb8ef10914d0aaf2c477b645116ef2f46a8411ef.png | simple | <table><tr><td><i>In vitro</i></td><td>Percentage of CD4<sup>+</sup>IL-10<sup>+</sup> (%)</td><td>MFI CD4<sup>+</sup>IL-10<sup>+</sup></td><td>iMFI CD4<sup>+</sup>IL-10<sup>+</sup></td></tr><tr><td>BALB/c</td><td>14·2 ± 1·2</td><td>125·0 ± 11·2</td><td>1775·0 ± 121·9</td></tr><tr><td>CBA</td><td>3·3 ± 0·2</td><td>82·1 ± 4·6</td><td>270·9 ± 15·6</td></tr></table> |
dd8bfce64fd29fc5fa843b08fc9b8b583192d4c0a85c4c41869671559c07e2b9.png | complex | <table><tr><td>Name</td><td>Forward and Revers Primers</td><td>Product Size</td><td>Comment</td></tr><tr><td rowspan="2">Bo 5S IGS</td><td>F: ACTAGGATGGGTGACCTCCCG;</td><td rowspan="2">484</td><td rowspan="2">5S-IGS product size</td></tr><tr><td>R: CGCTTAACTGCGGAGTTCTGA</td></tr><tr><td rowspan="2">Bo ITS1 and 2</td><td>F: CGCGAGAAGTCCACTAAACC;</td><td rowspan="2">823</td><td rowspan="2">Identify sequence differences</td></tr><tr><td>R: ACGTCCGATTTTCAAGCTGG</td></tr><tr><td rowspan="2">Bo 45S IGS</td><td>F: ATTCAGCCCTTTGTCGCTAA;</td><td rowspan="2">variable</td><td rowspan="2">45S-IGS product size</td></tr><tr><td>R: ATGACTACTGGCAGGATCAACCAG</td></tr><tr><td>IGS inter-D</td><td>ATCGTGTAGGACCGAGAAGT</td><td></td><td>D type intergenic</td></tr><tr><td>IGS inter-CEF</td><td>GGTAGGCACAAAAGGAATGC</td><td></td><td>C, E and F type intergenic</td></tr></table> |
dcede713f94629a2fa5783ee9066f1293797cbbfac179852069de429ea54c2db.png | complex | <table><tr><td>Variable of Interest</td><td></td><td><i>n</i></td><td>Mean</td><td>Standard Deviation</td><td>Notes</td></tr><tr><td>Age (years)</td><td></td><td>344</td><td>61.8</td><td>7.6</td><td></td></tr><tr><td>Age of menarche (years)</td><td></td><td>335</td><td>13.3</td><td>1.7</td><td>9 could not recall the age of menarche</td></tr><tr><td>Age of menopause (years)</td><td></td><td>327</td><td>49.9</td><td>5.8</td><td>17 had not reached menopause</td></tr><tr><td>Years since menopause (years)</td><td></td><td>327</td><td>11.9</td><td>9.4</td><td></td></tr><tr><td>Weight (kg)</td><td></td><td>344</td><td>60.5</td><td>11.3</td><td></td></tr><tr><td>Height (cm)</td><td></td><td>344</td><td>153.7</td><td>5.7</td><td></td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td></td><td>344</td><td>25.7</td><td>4.7</td><td></td></tr><tr><td>Body fat percentage (%)</td><td></td><td>344</td><td>36.2</td><td>7.0</td><td></td></tr><tr><td>Speed of sound (m/s)</td><td></td><td>344</td><td>1536.0</td><td>28.6</td><td></td></tr><tr><td>Broadband attenuation of sound (dB/MHz)</td><td></td><td>344</td><td>112.4</td><td>11.7</td><td></td></tr><tr><td>Stiffness index</td><td></td><td>344</td><td>84.8</td><td>14.5</td><td></td></tr><tr><td>T-score</td><td></td><td>344</td><td>−0.7</td><td>1.4</td><td></td></tr><tr><td>Total MET</td><td></td><td>344</td><td>2922.0</td><td>2046.8</td><td></td></tr><tr><td>Number of children (<i>n</i>)</td><td></td><td>344</td><td>2.9</td><td>1.8</td><td></td></tr><tr><td></td><td></td><td><i>n</i></td><td>%</td><td></td><td></td></tr><tr><td rowspan="3">Ethnicity</td><td>Chinese </td><td>119</td><td>34.6</td><td></td><td></td></tr><tr><td>Malay </td><td>197</td><td>57.3</td><td></td><td></td></tr><tr><td>Indian</td><td>28</td><td>8.1</td><td></td><td></td></tr><tr><td rowspan="4">Menopause status</td><td>Natural menopause</td><td>274</td><td>79.7</td><td></td><td></td></tr><tr><td>Menopause due to surgery</td><td>41</td><td>11.9</td><td></td><td></td></tr><tr><td>Menopause due to drugs</td><td>12</td><td>3.5</td><td></td><td></td></tr><tr><td>Perimenopausal</td><td>17</td><td>5</td><td></td><td></td></tr><tr><td rowspan="7">Education level</td><td>No formal education</td><td>17</td><td>4.9</td><td></td><td></td></tr><tr><td>Primary school</td><td>60</td><td>17.4</td><td></td><td></td></tr><tr><td>Secondary school</td><td>168</td><td>48.8</td><td></td><td></td></tr><tr><td>Certificate</td><td>31</td><td>9</td><td></td><td></td></tr><tr><td>Diploma</td><td>37</td><td>10.8</td><td></td><td></td></tr><tr><td>Degree</td><td>23</td><td>6.7</td><td></td><td></td></tr><tr><td>Postgraduate</td><td>8</td><td>2.3</td><td></td><td></td></tr><tr><td rowspan="3">Cigarette smoking status</td><td>Non-smoker</td><td>335</td><td>97.4</td><td></td><td></td></tr><tr><td>Current smoker</td><td>8</td><td>2.3</td><td></td><td></td></tr><tr><td>Ex-smoker</td><td>1</td><td>0.3</td><td></td><td></td></tr><tr><td rowspan="3">Alcohol drinking </td><td>Non-drinker</td><td>336</td><td>97.7</td><td></td><td></td></tr><tr><td>Current drinker</td><td>7</td><td>2.0</td><td></td><td></td></tr><tr><td>Ex-drinker</td><td>1</td><td>0.3</td><td></td><td></td></tr><tr><td rowspan="2">Milk drinking</td><td>Non-drinker</td><td>173</td><td>50.3</td><td></td><td></td></tr><tr><td>Drinker</td><td>171</td><td>49.7</td><td></td><td></td></tr><tr><td rowspan="3">Coffee drinking </td><td>Non-drinker</td><td>146</td><td>42.4</td><td></td><td></td></tr><tr><td>Current drinker</td><td>197</td><td>57.3</td><td></td><td></td></tr><tr><td>Ex-drinker</td><td>1</td><td>0.3</td><td></td><td></td></tr><tr><td rowspan="3">Physical activity status </td><td>Inactive</td><td>15</td><td>4.4</td><td></td><td></td></tr><tr><td>Minimally active</td><td>193</td><td>56.1</td><td></td><td></td></tr><tr><td>HEPA active</td><td>136</td><td>39.5</td><td></td><td></td></tr></table> |
c7bdd8ee1a3becb23807364cbdf8ea3b1b7b5543161329a4040f03c55721887a.png | complex | <table><tr><td>SPARQL Query</td><td>Note</td></tr><tr><td>SELECT DISTINCT ?label ?definitionContent ?ontologyId ?termId</td><td rowspan="9">To extract the definition and its metadata for a specific ICD category, A19 – Miliary tuberculosis</td></tr><tr><td> { GRAPH <http://who.int/icd></td></tr><tr><td>{ <http://who.int/icd#A19> <http://who.int/icd#definitionPrefilled> ?prefilledDefinition .</td></tr><tr><td><http://who.int/icd#A19> rdfs:label ?label .</td></tr><tr><td>?prefilledDefinition <http://who.int/icd#label> ?definitionContent;</td></tr><tr><td><http://who.int/icd#ontologyId> ?ontologyId;</td></tr><tr><td><http://who.int/icd#termId> ?termId;</td></tr><tr><td> </td></tr><tr><td>}}</td></tr></table> |
d7c27bc493f1cebc485a073d3a1914de6edab2eb6707e80103d6ba03c74c55d3.png | simple | <table><tr><td>Disease</td><td>Protein Defect</td><td>iNKT Cells</td><td>Type II NKT Cells</td><td>iNKT Cell Subsets</td></tr><tr><td>Gaucher</td><td>β-glucosidase (Glucocerebrosidase)</td><td>= [13]</td><td>↑ (glucosylsphingosine-specific) [13]</td><td>ND</td></tr><tr><td>Fabry</td><td>α-galactosidase A</td><td>= [71]</td><td>ND</td><td>↓ CD4+ iNKT cells [71]</td></tr><tr><td>NPC</td><td>NPC1</td><td>= [70]</td><td>ND</td><td>No alterations in CD4+ iNKT cells [70]</td></tr></table> |
7e1c67017510f4688c94a4ad8ff00969c26ab71cf26d4515aa7c83803006525a.png | simple | <table><tr><td>Collection Round</td><td>eHSR Trap Nights <sup>1</sup></td><td><i>Culex</i> spp. Ehsr <sup>1</sup></td><td><i>Culex</i> spp. Abundance Trap Nights <sup>2</sup></td><td><i>Culex</i> spp. Abundance <sup>2</sup></td><td>Nestlings</td><td>Culex: Nestlings</td><td>IR <sup>3</sup></td></tr><tr><td>1–15 June</td><td>43</td><td>0.4 ± 0.26</td><td>161</td><td>9.9 ± 1.09</td><td>107.2 ± 2.06</td><td>0.09</td><td>1.9</td></tr><tr><td>16–30 June </td><td>88</td><td>1.4 ± 1.13</td><td>172</td><td>10.2 ± 1.35</td><td>102.3 ± 3.75</td><td>0.1</td><td>0</td></tr><tr><td>1–13 July </td><td>34</td><td>0.1 ± 0.08</td><td>137</td><td>7.5 ± 1.21</td><td>33.9 ± 2.59</td><td>0.22</td><td>0</td></tr><tr><td>14–28 July </td><td>39</td><td>0.2 ± 0.08</td><td>187</td><td>9.7 ± 1.26</td><td>36.1 ± 1.27</td><td>0.27</td><td>1.7</td></tr><tr><td>29 July–11 August</td><td>24</td><td>0.1 ± 0.10</td><td>171</td><td>9.0 ± 1.95</td><td>19.4 ± 3.35</td><td>0.47</td><td>7.9</td></tr><tr><td>12–26 August </td><td>2</td><td>0 ± 0</td><td>206</td><td>5.9 ± 0.83</td><td>1.4 ± 0.53</td><td>4.15</td><td>2.1</td></tr></table> |
589e86f482c64476ea31cc02bff20611292b424150ed5a749366afec593005da.png | complex | <table><tr><td rowspan="2">Covariate</td><td colspan="2"><i>P </i>value</td><td colspan="2">Hazard radio</td><td colspan="2">95% Confidence interval</td></tr><tr><td>Univariate</td><td>Added SBEM</td><td>Univariate</td><td>Added SBEM</td><td>Univariate</td><td>Added SBEM</td></tr><tr><td>SBEM (3+ <i>vs.</i> <3+)</td><td>0.000</td><td>0.000</td><td>4.113</td><td>4.113</td><td>2.004-8.440</td><td>2.004-8.440</td></tr><tr><td>Lymph Node (Pos. <i>vs.</i> Neg.)</td><td>0.000</td><td>0.000</td><td>2.972</td><td>2.734</td><td>1.777-4.970</td><td>1.617-4.623</td></tr><tr><td>Age (>35Y <i>vs.</i> ≤35Y)</td><td>0.646</td><td>0.942</td><td>1.140</td><td>0.979</td><td>0.652-1.992</td><td>0.551-1.738</td></tr><tr><td>Tumor size (>20 mm <i>vs.</i> ≤20 mm)</td><td>0.308</td><td>0.367</td><td>0.771</td><td>0.794</td><td>0.468-1.271</td><td>0.481-1.311</td></tr><tr><td>Grade (>1 <i>vs.</i> =1)</td><td>0.066</td><td>0.085</td><td>0.563</td><td>1.720</td><td>0.305-1.040</td><td>0.928-3.188</td></tr><tr><td>Grade (=3 <i>vs.</i> ≤2)</td><td>0.001</td><td>0.004</td><td>3.036</td><td>2.688</td><td>1.572-5.864</td><td>1.371-5.273</td></tr><tr><td>TNM (>1 <i>vs.</i> =1)</td><td>0.000</td><td>0.000</td><td>3.164</td><td>2.769</td><td>1.918-5.218</td><td>1.705-4.498</td></tr><tr><td>TNM (=3 <i>vs.</i> ≤2)</td><td>0.000</td><td>0.001</td><td>4.000</td><td>3.565</td><td>1.987-8.055</td><td>1.734-7.332</td></tr><tr><td>Ki67 (≤35 <i>vs.</i> > 35)</td><td>0.001</td><td>0.004</td><td>2.956</td><td>2.597</td><td>1.585-5.512</td><td>1.362-4.950</td></tr></table> |
471fa526b9ecda9389b2e1d39ab8ab0f051af42025e5227b48b0a67c97c1aa5c.png | simple | <table><tr><td>Properties</td><td>Rejuvenator A</td><td>Rejuvenator B</td><td>Test Method</td></tr><tr><td>Form</td><td>Liquid</td><td>Liquid</td><td></td></tr><tr><td>Color</td><td>pink</td><td>Brown</td><td></td></tr><tr><td>pH</td><td>4.8</td><td>5.6</td><td>pH test paper</td></tr><tr><td>Viscosity (25 °C), SFS</td><td>40</td><td>15</td><td>ASTM D-244</td></tr><tr><td>Solute component [wt %]</td><td>65</td><td>60</td><td>ASTM D-244</td></tr><tr><td>Regeneration component [wt %]</td><td>8</td><td>8</td><td>ASTM D-2006-70</td></tr><tr><td>Asphaltene component [wt %]</td><td>0.4</td><td>0.75</td><td></td></tr></table> |
d3ba3e63838282f394bbb7abe82d537ec359667a50f918a79b1cbe9e7cc0a677.png | complex | <table><tr><td rowspan="2">CT and MRI Metrics</td><td colspan="2">ILD</td><td colspan="2">Non ILD</td></tr><tr><td>AUC</td><td><i>p</i> value</td><td>AUC</td><td><i>p</i> value</td></tr><tr><td colspan="5">CT</td></tr><tr><td>Main PA Diameter</td><td>0.873</td><td><0.001</td><td>0.835</td><td><0.001</td></tr><tr><td>PA/AA</td><td>0.799</td><td>0.003</td><td>0.794</td><td><0.001</td></tr><tr><td>PA Index</td><td>0.595</td><td>0.347</td><td>0.836</td><td><0.001</td></tr><tr><td>Right PA Diameter</td><td>0.753</td><td>0.012</td><td>0.757</td><td><0.001</td></tr><tr><td>Left PA Diameter</td><td>0.729</td><td>0.023</td><td>0.754</td><td><0.001</td></tr><tr><td colspan="5">MRI</td></tr><tr><td>Systolic PA area </td><td>0.887</td><td><0.001</td><td>0.824</td><td><0.001</td></tr><tr><td>Diastolic PA area </td><td>0.897</td><td><0.001</td><td>0.857</td><td><0.001</td></tr><tr><td>PA relative area change </td><td>0.388</td><td>0.266</td><td>0.365</td><td><0.001</td></tr></table> |
e7ea69945160cd921c669c945ad2816efb06f0232288ae195233bfc4aed642f6.png | simple | <table><tr><td></td><td>ME II</td><td>NFE II</td><td><i>P</i> Value</td><td>RR (95% confidence interval)</td></tr><tr><td>Prior admissions</td><td>19/23 (83%)</td><td>22/25 (88%)</td><td>NS</td><td></td></tr><tr><td>Prior intubation</td><td>9/30 (30%)</td><td>16/27 (59%)</td><td>0.03</td><td>1.97 (1–3.7)</td></tr><tr><td>B<sub>2</sub> agonist Use</td><td>23/25 (92%)</td><td>30/33 (91%)</td><td>NS</td><td></td></tr><tr><td>Inhaled corticosteroids</td><td>6/36 (17%)</td><td>16/33 (48%)</td><td>0.008</td><td>2.9 (1.2–6.5)</td></tr><tr><td>Systemic corticosteroids</td><td>11/36 (30%)</td><td>10/33 (30%)</td><td>NS</td><td></td></tr><tr><td>Cough</td><td>10/12 (83%)</td><td>15/20 (75%)</td><td>NS</td><td></td></tr><tr><td>Wheezing</td><td>10/12 (83%)</td><td>22/23 (96%)</td><td>NS</td><td></td></tr><tr><td>Sputum</td><td>6/10 (60%)</td><td>13/17 (76%)</td><td>NS</td><td></td></tr><tr><td>Chest tightness</td><td>3/6 (50%)</td><td>6/10 (60%)</td><td>NS</td><td></td></tr><tr><td>URTI</td><td>6/16 (37%)</td><td>7/15 (47%)</td><td>NS</td><td></td></tr><tr><td>Heart rate (beats/min)</td><td>102 ± 21(38)</td><td>124 ± 20(35)</td><td>0.0001</td><td></td></tr><tr><td>Respiratory rate (breaths/min)</td><td>25 ± 6(38)</td><td>32 ± 7(25)</td><td><0.0001</td><td></td></tr><tr><td>Systolic BP (mmHg)</td><td>136 ± 19(38)</td><td>147 ± 39(36)</td><td>NS</td><td></td></tr><tr><td>Diastolic BP (mmHg)</td><td>75 ± 18(37)</td><td>93 ± 25(34)</td><td>0.002</td><td></td></tr><tr><td>PO<sub>2</sub> (mmHg)</td><td>85 ± 33(25)</td><td>209 ± 170(34)</td><td>0.003</td><td></td></tr><tr><td>PCO<sub>2</sub> (mmHg)</td><td>41 ± 10(25)</td><td>57 ± 18(34)</td><td>0.001</td><td></td></tr><tr><td>pH</td><td>7.38 ± 0.06(24)</td><td>7.27 ± 0.12(34)</td><td>0.0001</td><td></td></tr><tr><td>FiO<sub>2</sub> (%)</td><td>40 ± 21(19)</td><td>71 ± 32(26)</td><td>0.001</td><td></td></tr><tr><td>A-aO<sub>2</sub> (mmHg)</td><td>136 ± 128(19)</td><td>188 ± 142(26)</td><td>0.09</td><td></td></tr><tr><td>WBC (mm<sup>3</sup>)</td><td>11,500 ± 4,000(29)</td><td>15,600 ± 6,200(25)</td><td>0.01</td><td></td></tr><tr><td>Eos (%)</td><td>1 ± 1.4(19)</td><td>2.75 ± 1.5(4)</td><td>0.03</td><td></td></tr><tr><td>Eos absolute (/mm<sup>3</sup>)</td><td>125 ± 198(19)</td><td>445 ± 324(4)</td><td>0.03</td><td></td></tr><tr><td>Hospitalization days</td><td>3.8 ± 2.6(27)</td><td>9.8 ± 5(7)</td><td>0.001</td><td></td></tr></table> |
e918fd9a16c202c94b8415aef10a3bed7eef7e5fbe75667a37447ce8c57c6250.png | simple | <table><tr><td>Phage density</td><td>Bacterial density</td><td>Implication</td></tr><tr><td>High</td><td>High</td><td>Low adsorption rate or partial bacterial refuge, poor control of bacteria. Gives insight to failure</td></tr><tr><td>High</td><td>Low</td><td>Not sustainable – a possible transitory step following successful control of bacteria, before phage densities have equilibrated</td></tr><tr><td>Low</td><td>High</td><td>Phage unable to replicate adequately; possible genetic resistance of bacteria or inaccessible refuge</td></tr><tr><td>Low</td><td>Low</td><td>Treatment success</td></tr></table> |
bd39cf2c632d5cfaa0a2f329a28cfaeddca155c7215e1afd0f210f7b3979a575.png | complex | <table><tr><td> </td><td colspan="2">Sango and Daiya</td><td> </td></tr><tr><td> </td><td>Within reach</td><td>Out of reach</td><td>χ<sup>2</sup>(1)</td></tr><tr><td>Robin and Daiya</td><td> </td><td> </td><td> </td></tr><tr><td>Within reach</td><td>32</td><td>62</td><td>0.92</td></tr><tr><td>Out of reach</td><td>114</td><td>174</td><td> </td></tr><tr><td>Koyuki and Daiya</td><td> </td><td> </td><td> </td></tr><tr><td>Within reach</td><td>32</td><td>30</td><td>6.12*</td></tr><tr><td>Out of reach</td><td>101</td><td>189</td><td> </td></tr><tr><td>Cherry and Daiya</td><td> </td><td> </td><td> </td></tr><tr><td>Within reach</td><td>9</td><td>26</td><td>2.84</td></tr><tr><td>Out of reach</td><td>120</td><td>177</td><td> </td></tr><tr><td>Chelsea and Daiya</td><td> </td><td> </td><td> </td></tr><tr><td>Within reach</td><td>7</td><td>45</td><td>16.39**</td></tr><tr><td>Out of reach</td><td>107</td><td>139</td><td> </td></tr><tr><td>Judy and Daiya</td><td> </td><td> </td><td> </td></tr><tr><td>Within reach</td><td>13</td><td>19</td><td>0.16</td></tr><tr><td>Out of reach</td><td>117</td><td>199</td><td> </td></tr></table> |
9b18d26a2a5d37dba6f45f297dd8189023ba65078c722d07600c15801483d2d5.png | complex | <table><tr><td></td><td colspan="4">Proportion of recurrence</td><td colspan="4">Proportion of death</td></tr><tr><td></td><td>Group 1</td><td>Group 2</td><td>Group 3</td><td>Group 4</td><td>Group 1</td><td>Group 2</td><td>Group 3</td><td>Group 4</td></tr><tr><td>Group 1</td><td>-</td><td>0.175</td><td><0.0001</td><td><0.0001</td><td>-</td><td>0.031</td><td><0.0001</td><td><0.0001</td></tr><tr><td>Group 2</td><td>-</td><td>-</td><td><0.0001</td><td><0.0001</td><td>-</td><td>-</td><td>0.013</td><td><0.0001</td></tr><tr><td>Group 3</td><td>-</td><td>-</td><td>-</td><td>0.080</td><td>-</td><td>-</td><td>-</td><td>0.057</td></tr><tr><td>Group 4</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr></table> |
6f1ab71bab9df4b227ade27db463108547754c89e3f92f04cdc83a298ad4729d.png | complex | <table><tr><td rowspan="2">Scale</td><td colspan="4">Cronbach’s alpha</td></tr><tr><td>Male</td><td>Female</td><td>Single</td><td>Married</td></tr><tr><td>Energy</td><td>0.87</td><td>0.87</td><td>0.76</td><td>0.81</td></tr><tr><td>Family role</td><td>0.77</td><td>0.72</td><td>0.39</td><td>0.79</td></tr><tr><td>Language</td><td>0.94</td><td>0.93</td><td>0.93</td><td>0.93</td></tr><tr><td>Self-care</td><td>0.93</td><td>0.92</td><td>0.94</td><td>0.92</td></tr><tr><td>Social role</td><td>0.90</td><td>0.84</td><td>0.85</td><td>0.89</td></tr><tr><td>Thinking</td><td>0.80</td><td>0.83</td><td>0.90</td><td>0.79</td></tr><tr><td>Mood</td><td>0.82</td><td>0.76</td><td>0.70</td><td>0.82</td></tr><tr><td>Personality</td><td>0.86</td><td>0.85</td><td>0.94</td><td>0.84</td></tr><tr><td>Upper extremity function</td><td>0.93</td><td>0.91</td><td>0.95</td><td>0.91</td></tr><tr><td>Vision</td><td>0.76</td><td>0.90</td><td>0.75</td><td>0.87</td></tr><tr><td>Work (productivity)</td><td>0.92</td><td>0.79</td><td>0.86</td><td>0.87</td></tr><tr><td>Mobility</td><td>0.95</td><td>0.92</td><td>0.95</td><td>0.93</td></tr></table> |
1096e25b8c724ec7d50d766cc22fe227dbc01ccd50e6bf88e25f3cf1a7e6f6fe.png | simple | <table><tr><td>Bands analyzed</td><td>Proteins detected</td><td>Database accession number</td><td>MOWSE score</td><td>Number of unique peptide identified</td><td>Sequence coverage, %</td><td>emPAI value</td></tr><tr><td>1</td><td>HoxF NAD-reducing hydrogenase diaphorase moiety large subunit [<i>R. eutropha</i> H16]</td><td>gi|38637753</td><td>4562</td><td>142</td><td>81</td><td>61.43</td></tr><tr><td>2</td><td>HoxH NAD-reducing hydrogenase moiety large subunit [<i>R. eutropha</i> H16]</td><td>gi|38637756</td><td>3401</td><td>112</td><td>71</td><td>48.36</td></tr><tr><td>3</td><td>HoxU NAD-reducing hydrogenase diaphorase moiety small subunit [<i>R. eutropha</i> H16]</td><td>gi|38637754</td><td>1692</td><td>61</td><td>87</td><td>194.61</td></tr><tr><td>4</td><td>HoxY NAD-reducing hydrogenase moiety small subunit [<i>R. eutropha</i> H16]</td><td>gi|32527093</td><td>474</td><td>18</td><td>61</td><td>7.91</td></tr><tr><td>5</td><td>HoxI [<i>R. eutropha</i> H16]</td><td>gi|38637758</td><td>2876</td><td>96</td><td>73</td><td>346.06</td></tr></table> |
602dd1f4a5cba9119410901632cceb045914c3e280bcb51084292dbfd7062b4b.png | simple | <table><tr><td>Study Outcome and Factors</td><td>2 Years <i>n</i> (%)</td><td>3.5 Years <i>n</i> (%)</td><td><i>p</i></td></tr><tr><td>Child outdoor playtime</td><td></td><td></td><td>0.126</td></tr><tr><td> <2 h/day</td><td>181 (37)</td><td>135 (33)</td><td></td></tr><tr><td> ≥2 h/day</td><td>305 (63)</td><td>379 (67)</td><td></td></tr><tr><td>Good neighbourhood to bring up child</td><td></td><td></td><td>0.418</td></tr><tr><td> No</td><td>99 (20)</td><td>74 (18)</td><td></td></tr><tr><td> Yes</td><td>395 (80)</td><td>339 (82)</td><td></td></tr><tr><td>Safe neighbourhood</td><td></td><td></td><td>0.875</td></tr><tr><td> No</td><td>48 (10)</td><td>39 (9)</td><td></td></tr><tr><td> Yes</td><td>443 (90)</td><td>373 (91)</td><td></td></tr><tr><td>Safe outdoor play</td><td></td><td></td><td><0.0001</td></tr><tr><td> No</td><td>125 (26)</td><td>174 (42)</td><td></td></tr><tr><td> Yes</td><td>358 (74)</td><td>236 (58)</td><td></td></tr><tr><td>Good parks or playgrounds</td><td></td><td></td><td>0.939</td></tr><tr><td> No</td><td>83 (17)</td><td>68 (17)</td><td></td></tr><tr><td> Yes</td><td>413 (83)</td><td>343 (83)</td><td></td></tr><tr><td>Traffic in neighbourhood</td><td></td><td></td><td>0.014</td></tr><tr><td> Heavy traffic</td><td>95 (19)</td><td>108 (26)</td><td></td></tr><tr><td> Not heavy traffic</td><td>398 (81)</td><td>306 (74)</td><td></td></tr><tr><td>Walk score</td><td></td><td></td><td>0.563</td></tr><tr><td> ≤49 (car-dependent) </td><td>237 (55)</td><td>197 (57)</td><td></td></tr><tr><td> >50 (walkable)</td><td>195 (45)</td><td>149 (43)</td><td></td></tr><tr><td>Population density</td><td></td><td></td><td>0.135</td></tr><tr><td> <18/hatch (mean)</td><td>232 (50)</td><td>204 (55)</td><td></td></tr><tr><td> ≥18/hatch (mean)</td><td>234 (50)</td><td>167 (45)</td><td></td></tr><tr><td>Accommodation type</td><td></td><td></td><td>0.083</td></tr><tr><td> Unit/townhouse</td><td>118 (24)</td><td>79 (19)</td><td></td></tr><tr><td> Free standing house</td><td>377 (76)</td><td>335 (81)</td><td></td></tr><tr><td>Number of vehicles in use</td><td></td><td></td><td>0.0002</td></tr><tr><td> 0 to 1 car</td><td>228 (47)</td><td>142 (35)</td><td></td></tr><tr><td> ≥2 cars</td><td>260 (53)</td><td>269 (65)</td><td></td></tr></table> |
39bd3c9471f84cb904bdba5df35a9390ed04556451367999f8d4d4c0e4959f57.png | complex | <table><tr><td>Subcategories of DRPs</td><td>Number of DRPs</td><td>%</td><td>resolved</td></tr><tr><td colspan="4">Doctors (N = 272)</td></tr><tr><td> Unnecessary therapy/No clinical indication</td><td>13</td><td>92.3%</td><td>(12/13)</td></tr><tr><td> Untreated indication</td><td>162</td><td>71.6%</td><td>(116/162)</td></tr><tr><td>Non reconciled medications</td><td>146</td><td>72.6%</td><td>(106/146)</td></tr><tr><td> Inappropriate duration</td><td>4</td><td>75.0%</td><td>(3/4)</td></tr><tr><td> Inappropriate dose schedule</td><td>11</td><td>54.5%</td><td>(6/11)</td></tr><tr><td> Dose too high</td><td>3</td><td>33.3%</td><td>(1/3)</td></tr><tr><td> Dose too low</td><td>1</td><td>0.0%</td><td>(0/1)</td></tr><tr><td> Drug-drug interactions</td><td>3</td><td>100.0%</td><td>(3/3)</td></tr><tr><td> Inappropriate/inadequate monitoring</td><td>1</td><td>0.0%</td><td>(0/1)</td></tr><tr><td> Prescription error</td><td>18</td><td>100.0%</td><td>(18/18)</td></tr><tr><td> Manifest side effect, no other cause</td><td>7</td><td>85.7%</td><td>(6/7)</td></tr><tr><td> More cost-effective drug available</td><td>3</td><td>66.7%</td><td>(2/3)</td></tr><tr><td> Deterioration/improvement of disease state</td><td>3</td><td>66.7%</td><td>(2/3)</td></tr><tr><td> Synergistic/preventive drug required and not given</td><td>19</td><td>63.2%</td><td>(12/19)</td></tr><tr><td> Duplication of therapy</td><td>10</td><td>90.0%</td><td>(9/10)</td></tr><tr><td> Prescribed drug not available</td><td>4</td><td>75.0%</td><td>(3/4)</td></tr><tr><td> Avoid contraindications</td><td>10</td><td>70.0%</td><td>(7/10)</td></tr><tr><td colspan="4">Nurses (<i>N</i> = 2)</td></tr><tr><td> Charting error</td><td>2</td><td>100.0%</td><td>(2/2)</td></tr></table> |
dbf162d183ad110487e65d56159d2dcbbb7ad3d65c5870aa468967ea854ffac9.png | complex | <table><tr><td></td><td colspan="4">Group V</td><td colspan="4">Group I</td></tr><tr><td></td><td>UAI</td><td></td><td>Univariate</td><td>Multivariate OR</td><td>UAI</td><td></td><td>Univariate</td><td>Multivariate OR</td></tr><tr><td></td><td>Row%</td><td>(n)</td><td>OR</td><td>(95%CI)</td><td>Row%</td><td>(n)</td><td>OR</td><td>(95%CI)</td></tr><tr><td><underline>Socio-demographics</underline></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Age groups</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 18-29</td><td>37.5</td><td><i>(72)</i></td><td>1.00</td><td>1.00</td><td>54.3</td><td><i>(69)</i></td><td>1.00</td><td>---</td></tr><tr><td> ≥30</td><td>25.0</td><td><i>(20)</i></td><td>0.56*</td><td>0.54(0.29,0.98)*</td><td>50.9</td><td><i>(28)</i></td><td>0.87</td><td></td></tr><tr><td>Number of items showing perceived discrimination against MSM (to the above 3 items)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0 - 2 discrimination responses</td><td>30.1</td><td><i>(63)</i></td><td>1.00</td><td>1.00</td><td>60.8</td><td><i>(45)</i></td><td>1.00</td><td>---</td></tr><tr><td> 3 discrimination responses</td><td>46.0</td><td><i>(29)</i></td><td>1.98*</td><td>2.33(1.28,4.26)**</td><td>48.1</td><td><i>(52)</i></td><td>0.60</td><td></td></tr><tr><td>Best friends supporting their sexual orientation</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No/unaware of one's sexual orientation</td><td>25.0</td><td><i>(20)</i></td><td>1.00</td><td>1.00</td><td>42.5</td><td><i>(34)</i></td><td>1.00</td><td>1.00</td></tr><tr><td> Yes</td><td>37.5</td><td><i>(72)</i></td><td>1.80*</td><td>1.97 (1.07, 3.62)*</td><td>61.8</td><td><i>(63)</i></td><td>2.19*</td><td>1.94(1.05,3.57)*</td></tr><tr><td>Number of friends having MSM behaviors</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> A few or none</td><td>34.7</td><td><i>(43)</i></td><td>1.00</td><td>---</td><td>47.9</td><td><i>(67)</i></td><td>1.00</td><td>1.00</td></tr><tr><td> All or most of them</td><td>33.3</td><td><i>(49)</i></td><td>0.94</td><td></td><td>71.4</td><td><i>(30)</i></td><td>2.72**</td><td>2.38(1.11,5.11)*</td></tr></table> |
3b865c95c4928b0683aa6e47d0b3625b8356f6e94c676f505b6df49724b56a1b.png | complex | <table><tr><td rowspan="2">Features</td><td><sup>1</sup>pSS Abs<sup>−</sup></td><td><sup>2</sup>pSS Abs<sup>+</sup></td><td><i>P</i><sup>*</sup></td></tr><tr><td>(<i>n</i> = 29)</td><td>(<i>n</i> = 23)</td><td>I-II</td></tr><tr><td>Age, mean ± SD years</td><td>56 ± 12</td><td>56 ± 13 </td><td>0.873</td></tr><tr><td>Schirmer's <i>I</i> test (mm/5 min), mean ± SD</td><td>3.17 ± 1.20</td><td>1.25 ± 1.12</td><td><0.0001</td></tr><tr><td>Unstimulated salivary flow (mL/15 min), mean ± SD</td><td>1.22 ± 0.20</td><td>0.83 ± 0.39</td><td>0.002</td></tr><tr><td>Biopsy focus score </td><td rowspan="2">1.17 (1/2)</td><td rowspan="2">2.40 (1/3)</td><td rowspan="2"><0.0001</td></tr><tr><td>(number of lymphocytic foci/4 mm<sup>2</sup>), mean (min/max)</td></tr><tr><td>Anti-SSA<sup>+</sup>, <i>n</i> (%)</td><td>0 (0)</td><td>6 (26)</td><td> </td></tr><tr><td>Anti-SSB<sup>+</sup>, <i>n</i> (%)</td><td>0 (0)</td><td>2 (9)</td><td> </td></tr><tr><td>BAFF, mean ± SD, ng/mL</td><td>4230 (1748)</td><td>5014 (2518)</td><td>0.187</td></tr><tr><td>Anti-SSA/SSB<sup>+</sup>, <i>n</i> (%)</td><td>0 (0)</td><td>15 (65)</td><td> </td></tr><tr><td>ESSPRI, mean (min/max)</td><td>8.39 (6/10)</td><td>9.1 (7/10)</td><td>0.075</td></tr><tr><td>ESSDAI, mean (min/max)</td><td>24.83 (21/30)</td><td>33.50 (27/39)</td><td><0.0001</td></tr></table> |
3b74ec3f61edd5df0d13892404ffdc426c960b16264a16d4e1f2b429ca54a563.png | simple | <table><tr><td>Compared organisms</td><td>CCMP1545</td><td>CCMP1545</td><td>RCC299</td><td>CCMP1545</td><td><i>O. lucimarinus</i></td></tr><tr><td>(pairs)</td><td>RCC299</td><td>CCMP2099</td><td>CCMP2099</td><td><i>O. lucimarinus</i></td><td><i>O</i>. RCC809</td></tr><tr><td>ID (%)</td><td>60</td><td>57</td><td>57</td><td>54</td><td>73</td></tr><tr><td>Coverage (%)</td><td>78</td><td>74</td><td>77</td><td>83</td><td>93</td></tr><tr><td>Gene fraction (%)</td><td>83</td><td>62</td><td>65</td><td>76</td><td>88</td></tr><tr><td>Ortholog count</td><td>8141</td><td>5859</td><td>6160</td><td>5534</td><td>6449</td></tr></table> |
9200e9b9169dbc44633b0275b1729cccdf085c5d3e76f77abacd06b924c4cf46.png | complex | <table><tr><td rowspan="2"></td><td colspan="4">Hbase and Phoenix</td><td colspan="4">Cassandra and Presto</td></tr><tr><td>Query 1</td><td>Query 2</td><td>Query 3</td><td>Query 4</td><td>Query 1</td><td>Query 2</td><td>Query 3</td><td>Query 4</td></tr><tr><td>3 nodes processing speed (s)</td><td>48.5</td><td>2.32</td><td>80.2</td><td>78.5</td><td>40.1</td><td>2</td><td>25</td><td>13</td></tr><tr><td>5 nodes processing speed (s)</td><td>27.9</td><td>1.79</td><td>58</td><td>50.5</td><td>34.3</td><td>1.85</td><td>20</td><td>10</td></tr></table> |
e86f78d38114db8cc7cc1c1626d2dfbc608d41b82ea483fdf628648ae9e9d827.png | complex | <table><tr><td>EDAD</td><td colspan="2">♂</td><td colspan="2">♀</td><td></td><td colspan="2">♀♂</td></tr><tr><td></td><td>N</td><td>%</td><td>N</td><td>%</td><td>♀/♂ </td><td>N</td><td>%</td></tr><tr><td>< 20</td><td>3</td><td>50.00</td><td>3</td><td>50.00</td><td>1.00</td><td>6</td><td>2.46</td></tr><tr><td>20.1 - 30</td><td>4</td><td>33.33</td><td>8</td><td>66.67</td><td>2.00</td><td>12</td><td>4.92</td></tr><tr><td>30.1 - 40</td><td>9</td><td>32.14</td><td>19</td><td>67.86</td><td>2.10</td><td>28</td><td>11.48</td></tr><tr><td>40.1 - 50</td><td>20</td><td>28.17</td><td>51</td><td>71.83</td><td>2.55</td><td>71</td><td>29.10</td></tr><tr><td>50.1 - 60</td><td>20</td><td>29.41</td><td>48</td><td>70.59</td><td>2.40</td><td>68</td><td>27.87</td></tr><tr><td>60.1 - 70</td><td>6</td><td>13.64</td><td>38</td><td>86.36</td><td>6.33</td><td>44</td><td>18.03</td></tr><tr><td>70.1 - 80</td><td>4</td><td>26.67</td><td>11</td><td>73.33</td><td>2.75</td><td>15</td><td>6.15</td></tr><tr><td>TOTAL</td><td>66</td><td>27</td><td>178</td><td>73</td><td>2.70</td><td>244</td><td>100</td></tr></table> |
40084f8d5d9f1bea4f7f87e34613394e5100e82dc5ae9d867b33213853ff5274.png | complex | <table><tr><td rowspan="2">Pellet</td><td rowspan="2">kVp</td><td rowspan="2">mAs</td><td rowspan="2">Filter</td><td rowspan="2">iDose<sup>4</sup> level</td><td>No MoM THA baseline</td><td>MoM THA O-MAR off</td><td>MoM THA O-MAR on</td></tr><tr><td>CNR</td><td>CNR</td><td>CNR</td></tr><tr><td>L0</td><td>120</td><td>150</td><td>A</td><td>5</td><td>33.06</td><td>13.02</td><td>12.99</td></tr><tr><td>L5</td><td>120</td><td>150</td><td>A</td><td>5</td><td>22.74</td><td>13.01</td><td>19.24</td></tr><tr><td>L6</td><td>120</td><td>150</td><td>A</td><td>5</td><td>16.75</td><td>1.37</td><td>18.16</td></tr><tr><td>L8</td><td>120</td><td>150</td><td>A</td><td>5</td><td>23.12</td><td>5.18</td><td>4.19</td></tr><tr><td>L0</td><td>120</td><td>600</td><td>A</td><td>5</td><td>46.52</td><td>23.07</td><td>23.07</td></tr><tr><td>L5</td><td>120</td><td>600</td><td>A</td><td>5</td><td>41.18</td><td>26.31</td><td>37.11</td></tr><tr><td>L6</td><td>120</td><td>600</td><td>A</td><td>5</td><td>41.65</td><td>5.84</td><td>24.72</td></tr><tr><td>L8</td><td>120</td><td>600</td><td>A</td><td>5</td><td>29.71</td><td>7.32</td><td>5.74</td></tr><tr><td>L0</td><td>140</td><td>101</td><td>A</td><td>5</td><td>20.27</td><td>17.51</td><td>17.51</td></tr><tr><td>L5</td><td>140</td><td>101</td><td>A</td><td>5</td><td>18.60</td><td>8.98</td><td>14.02</td></tr><tr><td>L6</td><td>140</td><td>101</td><td>A</td><td>5</td><td>19.77</td><td>0.77</td><td>23.69</td></tr><tr><td>L8</td><td>140</td><td>101</td><td>A</td><td>5</td><td>22.94</td><td>6.61</td><td>4.64</td></tr><tr><td>L0</td><td>140</td><td>405</td><td>A</td><td>5</td><td>43.88</td><td>30.64</td><td>30.65</td></tr><tr><td>L5</td><td>140</td><td>405</td><td>A</td><td>5</td><td>27.55</td><td>19.98</td><td>30.69</td></tr><tr><td>L6</td><td>140</td><td>405</td><td>A</td><td>5</td><td>53.21</td><td>0.85</td><td>28.91</td></tr><tr><td>L8</td><td>140</td><td>405</td><td>A</td><td>5</td><td>40.34</td><td>8.51</td><td>6.13</td></tr></table> |
19ed0c09f1c3b569da775c47bcc94cfac15d5e841e7511c0a6a42a2239c859af.png | simple | <table><tr><td>Comparison</td><td>Pearson’s Correlation coefficient</td><td>R-squared value</td></tr><tr><td>NBME (raw) version V1 EM M4</td><td>0.51</td><td>0.26</td></tr><tr><td>NBME (scaled) version V1 EM M4</td><td>0.42</td><td>0.18</td></tr><tr><td>NBME (raw) version V2 EM M4</td><td>0.58</td><td>0.30</td></tr><tr><td>NBME (scaled) version V2 EM M4</td><td>0.41</td><td>0.13</td></tr></table> |
4d48182074db0a66f8eddfe4bf1ea5bfca78d69c00a6974e007a1501a61f0cff.png | complex | <table><tr><td>Temperature (°C)</td><td>SR<sup>a </sup>(%)</td><td colspan="4">Yields of hydrolyzed sugars from</td><td>Total yield (%)</td><td>CrI<sup>b </sup>(%)</td></tr><tr><td></td><td></td><td colspan="2">Soluble fraction</td><td colspan="2">Residue</td><td></td><td></td></tr><tr><td></td><td></td><td>Glucose (%)</td><td>Xylose (%)</td><td>Glucose (%)</td><td>Xylose (%)</td><td></td><td></td></tr><tr><td>120</td><td>99.1</td><td>0.1</td><td>0.0</td><td>3.8</td><td>0.0</td><td>3.1</td><td>60.4</td></tr><tr><td>140</td><td>96.1</td><td>0.3</td><td>0.7</td><td>5.9</td><td>5.3</td><td>6.1</td><td>62.0</td></tr><tr><td>160</td><td>85.1</td><td>0.3</td><td>29.9</td><td>23.3</td><td>21.5</td><td>29.3</td><td>67.4</td></tr><tr><td>180</td><td>70.0</td><td>1.1</td><td>65.1</td><td>50.5</td><td>9.8</td><td>56.4</td><td>69.4</td></tr><tr><td>200</td><td>66.7</td><td>2.3</td><td>15.7</td><td>74.7</td><td>4.1</td><td>65.2</td><td>74.7</td></tr><tr><td>220</td><td>62.7</td><td>1.2</td><td>0.0</td><td>72.6</td><td>1.3</td><td>58.8</td><td>ND<sup>c</sup></td></tr><tr><td>240</td><td>51.8</td><td>1.1</td><td>0.0</td><td>42.5</td><td>0.0</td><td>34.6</td><td>65.6</td></tr></table> |
30ee6332cc360f9091b3384185d9e8f7660b1f3c7efd78cae934ab0252b5cb4b.png | simple | <table><tr><td>Cluster name</td><td>Voxels</td><td>p</td><td><i>Z</i>-MAX</td><td>MNI coordinates (mm)</td><td>Anatomical regions</td></tr><tr><td>rIPS</td><td>2163</td><td>1.19E-06</td><td>3.82</td><td>32, − 72, 40</td><td>Right lateral occipital cortex</td></tr><tr><td>lIPS</td><td>1149</td><td>0.0011</td><td>3.53</td><td>-33, − 42, 41</td><td>Left superior parietal lobule, left angular gyrus</td></tr><tr><td>rFEF</td><td>1117</td><td>0.00141</td><td>3.52</td><td>30, − 2, 62</td><td>Right superior frontal gyrus</td></tr><tr><td>rSPL</td><td>735</td><td>0.031</td><td>3.28</td><td>14, − 71, 55</td><td>Right precuneus cortex, right superior parietal lobule</td></tr></table> |
5d915c89671cfab7329c6dea16b9b396c76c51aeef6aa00bdc938ab509582820.png | simple | <table><tr><td></td><td>Total</td><td>Participators</td><td>Non-participators</td><td><i>P</i></td></tr><tr><td></td><td>(n = 172)</td><td>(n = 114)</td><td>(n = 58)</td><td></td></tr><tr><td>Medical care</td><td></td><td></td><td></td><td></td></tr><tr><td> Advice by a physician to undergo screening</td><td>65 (40.4)</td><td>58 (53.7)</td><td>7 (13.2)</td><td>< 10<sup>-4</sup></td></tr><tr><td> Score for perceived accessibility of colonoscopy centres (1 to 5)</td><td>3.8 (1.2)</td><td>4.0 (1.2)</td><td>3.3 (1.1)</td><td>0.0011</td></tr><tr><td>Family</td><td></td><td></td><td></td><td></td></tr><tr><td> Index patient sex: female</td><td>84 (48.8)</td><td>58 (50.9)</td><td>26 (44.8)</td><td>0.45</td></tr><tr><td> Index patient age at time of diagnosis</td><td></td><td></td><td></td><td>0.49</td></tr><tr><td>≤ 45 years old</td><td>22 (12.8)</td><td>16 (14.0)</td><td>6 (10.3)</td><td></td></tr><tr><td>> 45 years old</td><td>150 (87.2)</td><td>98 (86.0)</td><td>52 (89.7)</td><td></td></tr><tr><td> Number of cases of colorectal cancer declared in first-degree relatives</td><td></td><td></td><td></td><td>0.1</td></tr><tr><td>0</td><td>45 (26.2)</td><td>26 (22.8)</td><td>19 (32.8)</td><td></td></tr><tr><td>1</td><td>116 (67.4)</td><td>79 (69.3)</td><td>37 (63.8)</td><td></td></tr><tr><td>≥ 2 *</td><td>11 (6.4)</td><td>9 (7.9)</td><td>2 (3.4)</td><td></td></tr><tr><td> Discussion about screening with all brothers and sisters</td><td>84 (49.7)</td><td>73 (65.2)</td><td>11 (19.3)</td><td>< 10<sup>-4</sup></td></tr><tr><td>Social network</td><td></td><td></td><td></td><td></td></tr><tr><td> Belonging to a social group</td><td>54 (32.0)</td><td>41 (36.9)</td><td>13 (22.4)</td><td>0.055</td></tr><tr><td> Number of contacts with friends or relatives per month</td><td></td><td></td><td></td><td>0.24</td></tr><tr><td>≤ 2</td><td>19 (12.6)</td><td>13 (12.6)</td><td>6 (12.5)</td><td></td></tr><tr><td>3 to 11</td><td>98 (64.9)</td><td>63 (61.2)</td><td>35 (72.9)</td><td></td></tr><tr><td>≥ 12</td><td>34 (22.5)</td><td>27 (26.2)</td><td>7 (14.6)</td><td></td></tr><tr><td> Structural support score (0 to 4)</td><td>2.3 (1.1)</td><td>2.4 (1.1)</td><td>2.1 (0.9)</td><td>0.13</td></tr><tr><td> Emotional support score (0 to 4)</td><td>3.4 (1.0)</td><td>3.5 (0.9)</td><td>3.2 (1.2)</td><td>0.039</td></tr><tr><td> Material support</td><td>153 (91.6)</td><td>103 (93.6)</td><td>50 (87.7)</td><td>0.24</td></tr></table> |
f365de98815b04d439165a1c21114c6e6f54e6f7c6589f14cae79f2cdab9e22f.png | simple | <table><tr><td>Exercise</td><td>CTR</td><td>SR</td><td>WR</td></tr><tr><td>AS</td><td>9.6/10.6</td><td>10.2/7.0*</td><td>7.07/10.1*</td></tr><tr><td>OHS</td><td>16.2/14.6</td><td>9.8/7.8*</td><td>8.7/7.8</td></tr><tr><td>FS</td><td>11.9/9.6</td><td>9.2/14.8*</td><td>5.0/11.5*</td></tr><tr><td>DL</td><td>8.2/7.7</td><td>4.8/7.9*</td><td>4.1/7.8*</td></tr></table> |
51199896c6f8ae53eade2ac025a8e580fcb51a84cecd1f2f75b168334fb86d2c.png | simple | <table><tr><td>Treatment or procedure</td><td>Number of patients</td><td>Proportion of patients</td></tr><tr><td>Laboratory examinations such as blood samples, urine stick test and cultivation</td><td>96</td><td>67.6%</td></tr><tr><td>Electrocardiography</td><td>64</td><td>45.1%</td></tr><tr><td>Diagnostic radiology procedures</td><td>42</td><td>29.6%</td></tr><tr><td>Medicine administered per orally, suppository or as an ointment</td><td>41</td><td>28.9%</td></tr><tr><td>Intravenous medicine or liquid</td><td>38</td><td>26.8%</td></tr><tr><td>Urinary catheterization</td><td>16</td><td>11.3%</td></tr><tr><td>Telemetry</td><td>11</td><td>7.7%</td></tr><tr><td>None</td><td>10</td><td>7.1%</td></tr><tr><td>Oxygen supplement</td><td>6</td><td>4.2%</td></tr><tr><td>Medicine administered subcutaneously, intramuscular or as an inhalation</td><td>6</td><td>4.2%</td></tr><tr><td>Other</td><td>5</td><td>3.5%</td></tr><tr><td>Invasive procedures</td><td>4</td><td>2.8%</td></tr></table> |
1642069ad4b9d1a65f36d9d6287caa1cfdc23eb33895f694626b85e88db414bc.png | complex | <table><tr><td rowspan="2">Surgeon pair</td><td colspan="3">Kappa values</td></tr><tr><td>Trial 1</td><td>Trial 2</td><td>Mean</td></tr><tr><td colspan="4">Right hip</td></tr><tr><td>1–2</td><td>0.48 (M)</td><td>0.48 (M)</td><td>0.48 (M)</td></tr><tr><td>1–3</td><td>0.74 (G)</td><td>0.63 (G)</td><td>0.69 (G)</td></tr><tr><td>1–4</td><td>0.84 (V)</td><td>0.82 (V)</td><td>0.83 (V)</td></tr><tr><td>2–3</td><td>0.5 (M)</td><td>0.47 (M)</td><td>0.49 (M)</td></tr><tr><td>2–4</td><td>0.37 (F)</td><td>0.48 (M)</td><td>0.43 (M)</td></tr><tr><td>3–4</td><td>0.72 (G)</td><td>0.63 (G)</td><td>0.67 (G)</td></tr><tr><td colspan="4">Left hip</td></tr><tr><td>1–2</td><td>0.44 (M)</td><td>0.59 (M)</td><td>0.52 (M)</td></tr><tr><td>1–3</td><td>0.53 (M)</td><td>0.83 (V)</td><td>0.68 (G)</td></tr><tr><td>1–4</td><td>0.72 (G)</td><td>0.57 (M)</td><td>0.65 (G)</td></tr><tr><td>2–3</td><td>0.49 (M)</td><td>0.45 (M)</td><td>0.47 (M)</td></tr><tr><td>2–4</td><td>0.54 (M)</td><td>0.36 (F)</td><td>0.45 (M)</td></tr><tr><td>3–4</td><td>0.53 (M)</td><td>0.43 (M)</td><td>0.48 (M)</td></tr></table> |
c5daef64bfdca522ccf409403dee55c11776cb27e37878dba0a8703fed6ddb38.png | simple | <table><tr><td>Strains</td><td></td><td>Functional Predictions</td><td>Total SNP(%)</td><td>Genes Affected(%)</td></tr><tr><td>C57BL/6J vs. DBA/2J</td><td>PolyPhen</td><td>Deleterious</td><td>1,755 (19.4%)</td><td>954 (26.1%)</td></tr><tr><td></td><td></td><td>Benign</td><td>6,757 (74.5%)</td><td>2,343 (64%)</td></tr><tr><td></td><td></td><td>Unknown</td><td>567 (6.3%)</td><td>367 (10.1%)</td></tr><tr><td></td><td></td><td>Total</td><td>9,079</td><td>3,664</td></tr><tr><td></td><td>PANTHER</td><td>Deleterious</td><td>1,285 (14.2%)</td><td>632(17.1%)</td></tr><tr><td></td><td></td><td>non-deleterious</td><td>4,678 (51.6%)</td><td>1,736 (47%)</td></tr><tr><td></td><td></td><td>Unknown</td><td>3,116 (34.4%)</td><td>1,329 (36%)</td></tr><tr><td></td><td></td><td>Total</td><td>9,079</td><td>3,697</td></tr><tr><td>C57BL/6J vs. 129S1/SvImJ</td><td>PolyPhen</td><td>Deleterious</td><td>796 (19.5%)</td><td>480 (24.9%)</td></tr><tr><td></td><td></td><td>Benign</td><td>2,995 (73.4%)</td><td>1,270(65.7%)</td></tr><tr><td></td><td></td><td>Unknown</td><td>293 (7.2%)</td><td>185 (9.6%)</td></tr><tr><td></td><td></td><td>Total</td><td>4,084</td><td>1,935</td></tr><tr><td></td><td>PANTHER</td><td>Deleterious</td><td>568 (14%)</td><td>327(16.9%)</td></tr><tr><td></td><td></td><td>non-deleterious</td><td>2,049 (50.2%)</td><td>913 (47.1%)</td></tr><tr><td></td><td></td><td>Unknown</td><td>1,467 (36%)</td><td>701 (36.2%)</td></tr><tr><td></td><td></td><td>Total</td><td>4,084</td><td>1,941</td></tr><tr><td>C57BL/6J vs. A/J</td><td>PolyPhen</td><td>Deleterious</td><td>2,350 (18.9%)</td><td>1,197(26.1%)</td></tr><tr><td></td><td></td><td>Benign</td><td>9,220 (74.2%)</td><td>2,889 (63%)</td></tr><tr><td></td><td></td><td>Unknown</td><td>865 (7%)</td><td>504 (11%)</td></tr><tr><td></td><td></td><td>Total</td><td>12,435</td><td>4,590</td></tr><tr><td></td><td>PANTHER</td><td>Deleterious</td><td>1,785 (14.4%)</td><td>798(17.1%)</td></tr><tr><td></td><td></td><td>non-deleterious</td><td>6,443 (51.9%)</td><td>2,154(46.1%)</td></tr><tr><td></td><td></td><td>Unknown</td><td>4,207 (33.9%)</td><td>1,724 (36.9%)</td></tr><tr><td></td><td></td><td>Total</td><td>12,435</td><td>4,676</td></tr></table> |
29b9812584002397a9049d8e1ebbd6fdc6137a5133267d6f482dfa0e95f12d45.png | simple | <table><tr><td>Step</td><td></td></tr><tr><td>1.</td><td>X μL <sup>125</sup>I is added to wobbling reaction vial</td></tr><tr><td>2.</td><td>250 μL phosphate buffer (0.5 M, pH 7.4) is added</td></tr><tr><td>3.</td><td>50 μL BoNT-A/ phosphate buffer (=50 μg BoNT-A) is added<sup>a</sup></td></tr><tr><td>4.</td><td>115-X μL phosphate buffer (0.1 M, pH 6.8) is added to adjust the reaction volume to 215 μL</td></tr><tr><td>5.</td><td>17.5 μL freshly prepared IODOGEN/acetonitrile solution (2.5 μg/35 μL) is added into the reaction mixture (start of reaction, <i>t</i> = 0)</td></tr><tr><td>6.</td><td>At <i>t</i> = 45 s, another 17.5 μL IODOGEN/acetonitrile solution (2.5 μg/35 μL) is added</td></tr><tr><td>7.</td><td>At <i>t</i> = 90 s, 100 μL ascorbic acid solution (25 mg/mL, pH 5.0) is added to stop the reaction and to reduce any formed S-Cl bonds</td></tr><tr><td>8.</td><td>At <i>t</i> = 4.30 min, 10 μL BSA (50 mg/mL) is added<sup>b</sup></td></tr><tr><td>9.</td><td>At <i>t</i> = 5.30 min, samples are taken for ITLC for determination of the labelling efficiency</td></tr><tr><td>10.</td><td>At <i>t</i> = 10 min, 360 μL reaction mixture is transferred to a syringe connected to a filter<sup>c</sup></td></tr><tr><td>11.</td><td>The reaction vial is rinsed by 640 μL phosphate buffer (0.1M, pH 6.8) and also transferred to the syringe connected to the filter<sup>c</sup></td></tr><tr><td>12.</td><td>The combined solution in the syringe is filtered and purified on a PD10 column with ascorbic acid solution (5 mg/mL, pH 5.0) as eluent, collected fractions were 0.5 mL</td></tr><tr><td>13.</td><td>Fractions with highest amount of <sup>125</sup>I-BoNT-A and the highest radiochemical purity are pooled</td></tr><tr><td>14.</td><td>Samples of the pooled <sup>125</sup>I-BoNT-A (fractions 6, 7, 8) are taken for ITLC</td></tr><tr><td>15.</td><td>Final product is diluted by BSA (1 mg/mL) till a concentration of 1 μg/100 μL and stored at 20°C</td></tr></table> |
5d214135b3daa7d70c358296b5b9a79f30c91eca99fe1f70cb9abc2b96051de5.png | simple | <table><tr><td>Patient</td><td>Sex/Age of onset</td><td>Mutations (exon)</td><td>Phenotype</td><td>Kayser-Freicher rings</td><td>Serum ceruloplasmin</td><td>Serum free copper</td><td>24 h urinary copper</td><td>AST</td><td>ALT</td><td>PT</td></tr><tr><td>Normal</td><td></td><td></td><td></td><td>–</td><td>20–35 mg/dL</td><td><15 μg/dL</td><td><60–100 μg</td><td><40 IU/L</td><td><40 IU/L</td><td>>70%</td></tr><tr><td>Patient 1</td><td>Male/8</td><td>p.Phe1026Tyr (exon 14),c.2866-2A > G(intron 12)</td><td>Hepatic, Neurologic</td><td>+</td><td>0.0032 mg/dL</td><td>49 μg/dL</td><td>580 μg</td><td>26.82 IU/L</td><td>20.1 IU/L</td><td>49%</td></tr><tr><td>Patient 2</td><td>Female/8</td><td>p.His251Alafs*19(exon 2),p.Ser105*(exon 2)</td><td>Hepatic</td><td>+</td><td>0.0190 mg/dL</td><td>low</td><td>150 μg</td><td>139.1 IU/L</td><td>116.9 IU/L</td><td>22%</td></tr><tr><td>Patient 3</td><td>Male/10</td><td>p.Pro868Profs*5(exon 11),p.Ser105*(exon 2)</td><td>Hepatic</td><td>+</td><td>0.0920 mg/dL</td><td>low</td><td>3639 μg</td><td>129.0 IU/L</td><td>55.7 IU/L</td><td>17%</td></tr></table> |
09c2f63c5185b59242cb2db46b7b1c6e52519e81718f3f21ba1e2e90ceb839dc.png | complex | <table><tr><td colspan="2">Variables</td><td>Number</td><td>Percent</td></tr><tr><td rowspan="3">Gravida (number of pregnancies)</td><td>1</td><td>78</td><td>24.4</td></tr><tr><td>2–4</td><td>183</td><td>57.2</td></tr><tr><td>> = 5</td><td>59</td><td>18.4</td></tr><tr><td rowspan="4">Parity (number of deliveries)</td><td>0</td><td>78</td><td>24.4</td></tr><tr><td>1</td><td>171</td><td>31.5</td></tr><tr><td>2–4</td><td>116</td><td>53.4</td></tr><tr><td>> = 5</td><td>25</td><td>7.8</td></tr><tr><td rowspan="3">Birth order</td><td>1</td><td>179</td><td>55.9</td></tr><tr><td>2–4</td><td>116</td><td>36.3</td></tr><tr><td>> = 5</td><td>25</td><td>7.8</td></tr><tr><td rowspan="2">Pregnancy Trimester during interview</td><td>Second trimester</td><td>115</td><td>35.9</td></tr><tr><td>Third trimester</td><td>205</td><td>64.1</td></tr><tr><td rowspan="2">Gestational Age where ANC started</td><td>Before 16 weeks</td><td>154</td><td>48.1</td></tr><tr><td>At or After 16 weeks</td><td>166</td><td>51.9</td></tr><tr><td rowspan="2">Number of ANC visits</td><td>2–3</td><td>232</td><td>72.5</td></tr><tr><td>≥ 4</td><td>88</td><td>27.5</td></tr><tr><td rowspan="2">Receiving information about the importance of IFA supplementation</td><td>No</td><td>139</td><td>43.4</td></tr><tr><td>Yes</td><td>181</td><td>56.6</td></tr><tr><td rowspan="2">Medical illness</td><td>No</td><td>288</td><td>90.0</td></tr><tr><td>Yes</td><td>32</td><td>10.0</td></tr><tr><td rowspan="2">Morning sickness</td><td>No</td><td>255</td><td>79.7</td></tr><tr><td>Yes</td><td>65</td><td>20.3</td></tr><tr><td rowspan="2">Side effects</td><td>No</td><td>234</td><td>83.1</td></tr><tr><td>Yes</td><td>86</td><td>26.9</td></tr></table> |
7d3e87c45d8031fdd9366c4c2f705acd38e422c62c53e86007967bfe119aacdf.png | complex | <table><tr><td>System</td><td>Complications</td></tr><tr><td>Neurologic</td><td>Cord compression syndrome</td></tr><tr><td> </td><td>Intracranial hypertension/hydrocephalus</td></tr><tr><td>Thoracic</td><td>Superior vena cava syndrome</td></tr><tr><td rowspan="4"> </td><td>Pericardial effusion/cardiac tamponade</td></tr><tr><td>Pleural effusion</td></tr><tr><td>Pulmonary thromboembolism</td></tr><tr><td>Massive hemoptysis</td></tr><tr><td>Abdominal</td><td>Intenstinal obstruction</td></tr><tr><td rowspan="4"> </td><td>Inflammatory intestinal changes</td></tr><tr><td>Biliary obstruction</td></tr><tr><td>Urinary tract obstruction</td></tr><tr><td>Bleeding complications</td></tr></table> |
86b030a3541d9efd13d91b86e07e0d99dee1c3eef8f7ec508d059e6b6179b2cb.png | simple | <table><tr><td>Category</td><td>No. (%)</td></tr><tr><td>Infection</td><td>331 (59.1)</td></tr><tr><td> Respiratory tract</td><td>166 (51.2)</td></tr><tr><td> Urinary tract</td><td>99 (30.6)</td></tr><tr><td> Intra-abdominal</td><td>39 (12.1)</td></tr><tr><td> Skin and soft tissue</td><td>18 (3.2)</td></tr><tr><td> Primary bacteremia/fungemia</td><td>10 (3.1)</td></tr><tr><td> Central nervous system</td><td>2 (0.6)</td></tr><tr><td> Bone & joint</td><td>2 (0.6)</td></tr><tr><td> Other</td><td>2 (0.6)</td></tr><tr><td>Non-infection</td><td>179 (32.0)</td></tr><tr><td> Drug fever</td><td>101 (56.4)</td></tr><tr><td> Post-procedure</td><td>24 (13.4)</td></tr><tr><td> Cancer fever</td><td>23 (12.8)</td></tr><tr><td> Transfusion related</td><td>7 (3.9)</td></tr><tr><td> Dehydration related</td><td>3 (1.7)</td></tr><tr><td> ICH related central fever<sup>a</sup></td><td>2 (1.1)</td></tr><tr><td>Other</td><td>19 (10.6)</td></tr><tr><td>Unknown</td><td>50 (8.9)</td></tr></table> |
b12e3659d31b4e062d68431bf407ec7ded6b179e10c9971369a16aa3589d5d02.png | complex | <table><tr><td>Parameters</td><td>Mutants</td><td colspan="2">Salt concentrations</td></tr><tr><td></td><td></td><td><i>R</i></td><td><i>P</i>-value</td></tr><tr><td>Early PCD</td><td>Col-0</td><td>0.869<sup>**</sup></td><td>0.00</td></tr><tr><td></td><td><i>ein2-5</i></td><td>0.972<sup>**</sup></td><td>0.00</td></tr><tr><td></td><td><i>ein3-1</i></td><td>0.913<sup>**</sup></td><td>0.00</td></tr><tr><td></td><td><i>ctr1-1</i></td><td>0.766<sup>*</sup></td><td>0.02</td></tr><tr><td></td><td>Total</td><td>0.556<sup>**</sup></td><td>0.00</td></tr><tr><td>Late PCD</td><td>Col-0</td><td>−0.18</td><td>0.65</td></tr><tr><td></td><td><i>ein2-5</i></td><td>0.809<sup>**</sup></td><td>0.01</td></tr><tr><td></td><td><i>ein3-1</i></td><td>0.51</td><td>0.16</td></tr><tr><td></td><td><i>ctr1-1</i></td><td>0.09</td><td>0.83</td></tr><tr><td></td><td>Total</td><td>0.380<sup>*</sup></td><td>0.02</td></tr></table> |
c39c0cd84f64a8f04d154e5f777ea0e35541d3b348a8021b982eccfe37089356.png | simple | <table><tr><td></td><td>Audio</td><td>Visual</td><td>Sim. dual</td><td>Seq. dual</td></tr><tr><td>Mean accuracy rate ± s.e.m. (%)</td><td>95.2 ± 1.6</td><td>97.3 ± 1.2</td><td>89.9 ± 1.9</td><td>94.9 ± 1.1</td></tr></table> |
74dbfc704bfc4f518cc8c7334ae2118d80ca86ef78fc4aeac21ce9f5d4da872f.png | simple | <table><tr><td> Histomorphometry<sup>1</sup></td><td>Sham control</td><td>Vehicle control</td><td>CAPT</td><td>P 31.25</td><td>P 62.5</td><td>P125</td><td>LOSA</td></tr><tr><td>Degenerative regions</td><td>1.73 ± 1.60</td><td>78.92 ± 8.56*</td><td>56.76 ± 10.36<sup>∗,#</sup></td><td>54.79 ± 10.93<sup>∗,#</sup></td><td>40.50 ± 12.92<sup>∗,#</sup></td><td>33.73 ± 5.77<sup>∗,#</sup></td><td>63.80 ± 10.24<sup>∗,##</sup></td></tr></table> |
607cb97e27ee908ccc809cf18832c1193c1b036c9d6b9ef3719e621f06b4a31b.png | simple | <table><tr><td>Dataset</td><td>No.of Training(class1/class2)</td><td>No.of Testing(class1/class2)</td></tr><tr><td>Leukaemia</td><td>50(32 ALL/18 AML)</td><td>22 (15 ALL/7 AML)</td></tr><tr><td>Prostate</td><td>71(35 ALL/36 AML)</td><td>31(15 ALL/16 AML)</td></tr><tr><td>Colon</td><td>42(14 Normal/28 Tumor)</td><td>20(8 Normal/12 Tumor)</td></tr><tr><td>DLBCL</td><td>60(45 DLBCL/15FL)</td><td>17(13 DLBCL/4 FL)</td></tr></table> |
857d3f7499598f19d4c356693d5647e94e963590e6b54e2259cb76b3415c861e.png | complex | <table><tr><td colspan="5">Disinfectants</td><td colspan="2">Neutralizing agents</td></tr><tr><td>Classification</td><td>Active ingredients</td><td>Recommended concentration</td><td>Recommended contact time</td><td>Optimal application</td><td>Active ingredients</td><td>Concentration</td></tr><tr><td>Aldehydes</td><td>Glutaraldehyde</td><td>4%</td><td>20 min</td><td>Equipment, goods</td><td>Glycine</td><td>2%</td></tr><tr><td rowspan="2">Halogens</td><td>Sodium hypochlorite</td><td>2 g/L</td><td>20 min</td><td>Biological material, smooth surface</td><td>Sodium thiosulfate</td><td>0.2%</td></tr><tr><td>Trichloroisocyanuric acid</td><td>4 g/L</td><td>30 min</td><td>Lab environment, Medical supplies</td><td>Sodium thiosulfate</td><td>0.4%</td></tr><tr><td>Quaternary ammonium compound</td><td>Benzalkonium chloride</td><td>0.2 g/L</td><td>/</td><td>Skin, mucous membranes</td><td>Tween-80 + Phosphatidylcholine</td><td>0.5% + 1%</td></tr><tr><td>Phenolic</td><td>Lysol</td><td>10 g/L</td><td>30 min</td><td>Object surface</td><td>Tween-80</td><td>1%</td></tr><tr><td>Alkaline</td><td>Sodium hydroxide</td><td>10 g/L</td><td>/</td><td>Field, animal housing</td><td>Hydrochloric acid</td><td>10%</td></tr></table> |
d647b963beb27b59c5751c325e854542677cf91f9313a7d617524890eac44e53.png | simple | <table><tr><td>Code</td><td>Features</td><td>Preparation room use</td></tr><tr><td>A</td><td>No Intubation</td><td>NO</td></tr><tr><td>B</td><td>General Anesthesia and Intubation</td><td>NO</td></tr><tr><td>C</td><td>B + One Procedure</td><td>NO / YES</td></tr><tr><td>D</td><td>B + More Than One Procedure</td><td>NO / YES</td></tr></table> |
a4e2d993cab077d3d4427402a4d2354c169e147a1f63155fa4ae9d78c9f0a264.png | complex | <table><tr><td>Categorical variables</td><td>N* (n = 199)</td><td>%</td><td>Crude</td><td>p value**</td></tr><tr><td>Continuous variables<sup>#</sup></td><td> </td><td>Mean(SD)</td><td>OR</td><td> </td></tr><tr><td><i>Home ownership</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Own home (fully owned or mortgaged)</td><td>162</td><td>4.9%</td><td>1</td><td rowspan="2">0.027</td></tr><tr><td> Rented, gifted or invaded</td><td>37</td><td>16.2%</td><td>3.726</td></tr><tr><td><i>Electric power supply</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Lacking</td><td>22</td><td>22.7%</td><td>1</td><td rowspan="2">0.011 '</td></tr><tr><td> Present</td><td>177</td><td>5.1%</td><td>0.182</td></tr><tr><td><i>Wealth index</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Richer half</td><td>104</td><td>1.9%</td><td>1</td><td rowspan="2">0.004 '</td></tr><tr><td> Poorer half</td><td>95</td><td>12.6%</td><td>7.373</td></tr><tr><td><i>Mother schooling (years)</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Did not go to school</td><td>8</td><td>37.5%</td><td>1</td><td rowspan="3">< 0.001</td></tr><tr><td> 1 to 4 years</td><td>27</td><td>7.4%</td><td>0.013</td></tr><tr><td> Above 4 years</td><td>81</td><td>1.2%</td><td>0.002</td></tr><tr><td> <i>p linear tendency</i></td><td> </td><td> </td><td> </td><td><i>0.003</i></td></tr><tr><td><i>Maternal height (cm)</i><sup><i>#</i></sup></td><td>186</td><td>158.5 (5.29)</td><td>0.855</td><td>0.01</td></tr><tr><td><i>Number of pregnancies</i><sup><i>#</i></sup></td><td>113</td><td>2.63 (2.21)</td><td>1.35</td><td>0.018</td></tr><tr><td><i>Anaemia diagnosis</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No</td><td>69</td><td>49.64%</td><td>1</td><td>0.176</td></tr><tr><td> Yes</td><td>70</td><td>50.36%</td><td>3.09</td><td> </td></tr></table> |
054dfe2ac2a865730ab709081de50d8607ff37ee44f31b2b32065f47f953d75d.png | simple | <table><tr><td>Country</td><td>Maize</td><td>Other major crops</td></tr><tr><td>Bangladesh</td><td>No</td><td>Eggplant</td></tr><tr><td>India</td><td>No</td><td>Cotton, soybean</td></tr><tr><td>Iran</td><td>No</td><td>Rice</td></tr><tr><td>Myanmar</td><td>No</td><td>Cotton</td></tr><tr><td>Pakistan</td><td>No</td><td>Cotton</td></tr><tr><td>Australia</td><td>Yes</td><td>Alfalfa, canola, cotton, potato, rice, soybean, wheat</td></tr><tr><td>China</td><td>Yes</td><td>Canola, cotton, maize, rice, soybean</td></tr><tr><td>Indonesia</td><td>Yes</td><td>Soybean, sugarcane</td></tr><tr><td>Japan</td><td>Yes</td><td>Alfalfa, canola, cotton, potato, soybean</td></tr><tr><td>Malaysia</td><td>Yes</td><td>Soybean</td></tr><tr><td>New Zealand</td><td>Yes</td><td>Alfalfa, canola, cotton, potato, rice, soybean, wheat</td></tr><tr><td>Philippines</td><td>Yes</td><td>Alfalfa, canola, cotton, potato, rice, soybean</td></tr><tr><td>Singapore</td><td>Yes</td><td>Alfalfa, canola, cotton, maize, soybean</td></tr><tr><td>South Korea</td><td>Yes</td><td>Alfalfa, canola, cotton, potato, soybean</td></tr><tr><td>Thailand</td><td>Yes</td><td>Soybean</td></tr><tr><td>Turkey</td><td>Yes</td><td>Soybean</td></tr><tr><td>Vietnam</td><td>Yes</td><td>None</td></tr></table> |
74d4235da1bdf4e3c8304df0c02139f38e9076496659d3a36cae1ad75d0f5aa9.png | complex | <table><tr><td>Strain</td><td colspan="4">24 hours</td><td colspan="4">48 hours</td></tr><tr><td></td><td>Product(mg/L)</td><td colspan="3">Intermediates(mg/L)</td><td>Product(mg/L)</td><td colspan="3">Intermediates(mg/L)</td></tr><tr><td></td><td>caffeic acid</td><td>tyrosine</td><td><i>p</i>-coumaric acid</td><td><i>L</i>-dopa</td><td>caffeicacid</td><td>tyrosine</td><td><i>p</i>-coumaric acid</td><td><i>L</i>-dopa</td></tr><tr><td>YL-2</td><td>11.1 ± 1.1</td><td>< 0.2</td><td>< 0.2</td><td>< 0.2</td><td>12.1 ± 0.3</td><td>< 0.2</td><td>< 0.2</td><td>7.4 ± 0.2</td></tr><tr><td>YL-2*</td><td>20.2 ± 1.8</td><td>< 0.2</td><td>< 0.2</td><td>2.1 ± 0.3</td><td>21.5 ± 4.0</td><td>< 0.2</td><td>< 0.2</td><td>14.2 ± 1.7</td></tr><tr><td>YL-3</td><td>-</td><td>188.9 ± 5.7</td><td>-</td><td>-</td><td>-</td><td>296.6 ± 1.0</td><td>-</td><td>-</td></tr><tr><td>YL-4</td><td>-</td><td>218.6 ± 8.2</td><td>-</td><td>-</td><td>-</td><td>426.7 ± 4.9</td><td>-</td><td>-</td></tr><tr><td>YL-5</td><td>30.5 ± 1.9</td><td>17.1 ± 1.8</td><td>2.9 ± 0.3</td><td>15.4 ± 1.7</td><td>50.2 ± 10.1</td><td>25.1 ± 2.5</td><td>< 0.2</td><td>75.3 ± 13.6</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.